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Resumo 
 
Chlamydia trachomatis possui um ciclo de desenvolvimento intracelular único que termina pela 
lise da célula e/ou extrusão das bactérias a fim de permitir re-infecções. Esta é uma infeção 
maioritariamente assintomática, sendo o diagnóstico de Chlamydia trachomatis geralmente tardio, ou 
seja, após a manifestação de persistência. Investigações sobre as consequências destas infecções a 
longo prazo e dos mecanismos moleculares adjacentes irão elucidar de que forma as bactérias podem 
modular as funções da célula hospedeira e qual o destino final destas após uma infecção. Tais estudos 
podem ser grandemente facilitados se as células infectadas se tornarem permanentemente marcadas 
durante e após a infecção. Desta forma, este projeto tem como objetivo o desenvolvimento de uma nova 
ferramenta genética que torne possível a rotulagem permanente das células infectadas por Chlamydia 
trachomatis. O plano foi o de gerar uma estirpe de Chlamydia trachomatis que codifica uma recombinase, 
CRE, agregada a uma proteína efectora do sistema de secreção tipo 3 (T3SS) da Chlamydia. Após a 
translocação para a célula hospedeira, a enzima recombinante CRE, devido à sua função de 
recombinação local específica, irá activar um gene repórter contido no genoma da célula hospedeira. 
Para este fim, a linha celular repórter usada contém um gene membrane-tagged, tdTomato (mT), 
flanqueado por duas sequências LoxP, seguido por um gene GFP. A translocação da CRE recombinase 
para esta linha celular irá promover a recombinação dos locais LoxP através dos quais as células 
infectadas alteram de fluorescência vermelha para verde de uma forma irreversível. A execução bem-
sucedida deste mecanismo permitirá estabelecer uma relação direta entre a infecção por Chlamydia 
trachomatis e o destino posterior da célula infectada. 
 
Termos-chave: Chlamydia trachomatis, Sistema de Secreção tipo 3, TARP, Clonagem, 
Manipulação genética, Sistema de recombinação CRE/LoxP. 
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Abstract 
 
Chlamydia trachomatis has a unique obligate intracellular developmental cycle that ends by the 
lysis of the cell and/or the extrusion of the bacteria in order to allow for re-infections. While Chlamydia 
trachomatis infections are often asymptomatic the diagnosis of Chlamydia trachomatis is usually late, 
occurring after manifestation of persistency. Investigations on the consequences of long-term infections 
and the molecular mechanisms behind it will reveal light to what extent bacteria can modulate host cell 
function and what the ultimate fate of host cells after clearance of an infection is. Such studies on the host 
cell fate could be greatly facilitated if the infected cells become permanently marked during and after the 
infection. Therefore, this project intends to develop a new genetic tool that would allow permanently 
labeling of Chlamydia trachomatis host cells. The plan was to generate a Chlamydia trachomatis strain 
that encodes a recombinant CRE recombinase, fused to a secretory effector function of the Chlamydia 
type 3 secretion system (T3SS). Upon translocation into the host cell, this recombinant CRE enzyme 
could then, owing to its site-specific recombination function, switch a reporter gene contained in the host 
cell genome. To this end, the reporter line carried a membrane-tagged tdTomato (mT) gene flanked by 
two LoxP sequences followed by a GFP gene. The translocation of the recombinant CRE recombinase 
into this cell line was designed to trigger the recombination of the LoxP sites whereby the cells would turn 
from red fluorescence to green as an irreversible label of the infected cells. Successful execution of this 
mechanism would allow to draw a direct link between Chlamydia trachomatis infection and the 
subsequent fate of the infected cell. 
 
Keywords: Chlamydia trachomatis, Type 3 Secretion System, TARP, Cloning, Genetic 
Transformation, CRE/LoxP recombination system.  
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I. Introduction 
1. Chlamydia spp. 
The family Chlamydiaceae is integrated by gram-negative bacteria that infect the ocular, genital 
and pulmonary surfaces. It is reunited into a single genus, Chlamydia, which involves nine species: 
Chlamydia trachomatis, Chlamydia muridarum, Chlamydia pneumoniae, Chlamydia pecorum, Chlamydia 
suis, Chlamydia abortus, Chlamydia felis, Chlamydia caviae, and C. psittaci. These species exhibit major 
differences in host range, tissue tropism, and disease pathology and affect a wide range of vertebral 
hosts, causing infections with serious impact on human health and on farming and veterinary industries 
(Agaisse and Derré, 2013; Betts-Hampikian and Fields, 2010; Bush and Everett, 2001; Nunes and 
Gomes, 2014). Species were grouped according to their biologic and biochemical properties, their 
homology in the 16s ribosomal RNA sequences and their gene for the major outer-membrane protein 
(MOMP) (Bush and Everett, 2001; Peeling and Brunham, 1996).  
 
A. Pathogenesis and Biology of Chlamydia trachomatis 
Ctr isolates are divided into, at least, fifteen serologically defined variants (serovars) which are 
associated with different pathologies, including blinding trachoma (serovars A–C), urogenital tract 
infections leading to urethritis, cervicitis, and proctitis (serovars D–K) and systemic lymphogranuloma 
venereum (LGV) disease (serovars L1, L2 and L3) (Bastidas et al., 2013; Bauler and Hackstadt, 2014; 
Wang et al., 2013a). Ctr is the most frequently reported cause of sexually transmitted disease worldwide, 
with an occurrence of approximately 100 million cases per year (WHO, 2011). The incidence of reported 
confirmed cases increased by 41%, between 2006 and 2010, in EU/EEA countries (ECDC, 2012). The 
most common serovar detected worldwide is E (up to 22 to 49% of cases) followed by serovars F and D 
(17 to 22% and 9 to 19%, respectively), while other serovars are less frequently identified 
(Papadogeorgakis et al., 2010). Like other sexually transmitted infections, it is primarily a women‘s care 
issue since the manifestations and consequences are more damaging to the reproductive health of 
women than men (Paavonen and Eggert-Kruse, 1999). One of the biggest complications is that, 
regardless of the gender, the majority of the infections, remain asymptomatic and difficult to diagnosed; 
hence bacteria persist for month, or even years. Persistence and recurrent infections with Ctr can often 
lead to infertility due to tubal occlusion and pelvic inflammatory diseases (Chin et al., 2012; ECDC, 2012; 
Kessler et al., 2012; Land et al., 2010). In Europe and United States of America, Ctr infection is the main 
cause of tubal infertility, which increase directly proportional to the number of pelvic infections in the past 
(Wilkowska-Trojniel et al., 2009).  
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 It has been recently implied that chronic bacterial disease can have a direct role in 
carcinogenesis, in the case of Chlamydia several studies have been made in the intend to correlate this 
pathogen with cervical and ovarian cancer (Arnheim Dahlström et al., 2011; Koskela et al., 2000; 
Shanmughapriya et al., 2012).  
Chlamydia developmental compromises a very complex cycle divided in two main forms (Figure 
I.1). The infection starts with the attachment of the elementary bodies (EBs) (the infectious and 
metabolically inactive ‗spore-like‘ form of the bacteria used to extracellular survival) to the surface of the 
host cells. After attachment Chlamydia induces the Rho-GTPase Rac1 and the chlamydial protein TARP 
(Translocated Actin Recruitment Protein) is translocated to the host cell, resulting in an actin-
rearrangement allowing the entry of the EBs. The arising phagocyte compartment is rapidly modified by 
proteins derived from Chlamydia generating a replicative niche termed inclusion (Bastidas et al., 2013; 
Bauler and Hackstadt, 2014; Valdivia, 2008). Within the inclusion the EBs that has a rigid cell wall 
conferred by extensive disulfide cross-linking of the major outer membrane protein (MOMP), differentiate 
into reticulate bodies (RBs), the active and replicative form of the bacteria. Afterwards, RBs undergo 
several replicative cycles within the inclusion that is intimately associated with recycling endosomes that 
translocate through a dynein-dependent mechanism to the peri-Golgi region and replicates by binary 
fission. During this stage, a subset of Rab GTPases are recruited to the inclusion membrane and the 
inclusion expands becoming the replication asynchronous in the differentiation from RBs back into the 
EBs form (Bastidas et al., 2013; Beatty et al., 1994; Engel, 2004; Valdivia, 2008; Wang et al., 2013a). 
Eventually most of the cytoplasmic space of the host cell is occupied by the inclusion and the newly 
formed EBs are further released from the host cell, by cell lysis (sequential disruption of the inclusion and 
cellular membranes by cysteine proteases) and/or extrusion (package release out of the cell within a cell 
membrane compartment, and ultimately detachment from the cell) (Hybiske and Stephens, 2007). 
During the infection cycle on the host cell, when Chlamydia is subjected to stress (e.g. tryptophan 
starvation, exposed to beta lactam antibiotics) the developmental cycle slows and ceases to divide; also, 
the transition to EB becomes retarded. This results in aberrant RB formation where the RBs become 
enlarged and the developmental cycle enters into a persistent, non-infectious state. Like other stressed 
bacteria, these aberrant RBs express elevated levels of stress-response proteins and do not resume 
normal growth until the stressor is removed (Peters et al., 2010; Skilton et al., 2009; Wang et al., 2013a). 
In the specific case of penicillin treatment, this will not affect EB to RB differentiation but it will inhibit 
chromosomal condensation and, consequently, the transition from replicating RBs to infectious EBs in the 
later stages of the developmental cycle (Skilton et al., 2009). 
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Figure I.1 Life cycle of Chlamydia trachomatis. Within the first 2 h following internalization into cells, 
elementary bodies (EBs) fuse to form a nascent inclusion. Between 2 h and 6 h post-internalization, EBs begin to 
differentiate into reticulate bodies (RBs). By 12 h post-infection (h.p.i.) RBs can be observed dividing by binary fission 
(18–24 h.p.i.). Increasing numbers of RBs differentiate back to EBs around 24 h.p.i. and continue differentiating until 
lysis and/or extrusion (48–72 h.p.i.) (Adapted from Bastidas et al. 2013). 
 
 
B. Type 3 Secretion System 
At both forms of the chlamydial cycle, effector proteins are translocated directly into the host cell 
for manipulation of diverse host-cellular functions, using a Type 3 Secretion System (T3SS) (Olive et al., 
2014). The non-flagelar T3SS, Figure I.2, is composed by: Ancillary Components (AC) containing 
secretion signals and chaperons, essential for the translocation of the effector protein through the 
molecular syringe; the Basal Apparatus that is composed for different proteins that connect the outer and 
inner membrane of the inclusion. The exterior components are composed by the Needle Complex (NC), 
which consists of a membrane-embedded basal structure, that will connect the bacteria and the 
membrane of the host cell for translocation; the Tip Complex (TP) that only exist under non-secreting 
conditions and the Translocator proteins (Tr) which oligomerize to form a hetero-oligomeric pore in the 
host cell cytoplasmic membrane and the inclusion membrane (Betts-Hampikian and Fields, 2010; 
Chatterjee et al., 2013; Peters et al., 2010).  
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The T3SS system assembly is initiated by three structural proteins (CdsC, CdsJ and CdsD) that 
assemble the Basal Apparatus. As soon this structure is completed, components can be exported to form 
the NC that protrudes from the bacterial surface, and the TC that caps the needle (Betts-Hampikian and 
Fields, 2010).  
 
 
 
Figure I.2 Schematic representation of a Type 3 secretion injectisome. Components include: the 
translocator (Tr), tip complex (TC), needle complex (NC), basal apparatus, and cytoplasmic ancillary proteins (AC). 
The basal apparatus is within the bacterial inner membrane (IM), the periplasm (PP) and outer membrane (OM). 
Secreted components are shown localized to a host membrane (HM) (Betts-Hampikian and Fields, 2010). 
 
C. Chamydial effectors 
The knowledge of the cellular processes that are targeted by Ctr has greatly increased over the 
past 10-15 years, but only recently the effort to identify the host and bacterial factors required for bacterial 
development had begun (Derré et al., 2011). Numerous Ctr T3S substrates, between other features of Ctr 
have been found by using Salmonella, Shigella or Yersinia as heterologous hosts, or suggested by 
machine learning algorithms based on the N-terminal T3S signal of known effectors (Pais et al., 2013). 
It is estimated that Ctr genomes may encode approximately one-hundred T3S substrates (Pais et 
al., 2013). T3S substrates display little sequence homology, although they often display common 
structural features and have similar enzymatic activities across bacterial strains. These proteins are either 
secreted into the inclusion lumen, deposited in the inclusion membrane or translocated directly to the 
cytosol of the host cell (Peters et al., 2010).  
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The Chlamydia inclusion contains 50 membrane proteins, including a number of proteins that 
show no sequence similarities but have in common the presence of a large (40±70 amino acids) 
hydrophobic region and have therefore been grouped into a structural family called the Inc family (Derré et 
al., 2011; Subtil et al., 2001). These proteins are localized at the inclusion membrane and are known to be 
produced early in the chlamydial infectious process and consequently are candidates for initial pathogen-
host cell interactions that lead to the formation of the inclusion (Bastidas et al., 2013; Rockey et al., 2002). 
The inclusion proteins identified go from IncA to IncG and only a few of them have established functions; 
for example, IncA, IncB and IncC are consider as probably the major components of the inclusion, with 
functions likely involved in the homotypic fusion of the Ctr inclusions (Derré et al., 2011; Subtil et al., 
2001). 
Between the translocated substrates, in 2004, Clifton and coworkers reported that on entry, Ctr 
translocate an actin-recruiting protein (TARP) into the host cell, that corresponds to the chlamydial ORF 
CT456, which encodes a 103-kDa protein (Clifton et al., 2004; Engel, 2004). TARP protein becomes 
tyrosine phosphorylated by a host cell kinase, and is spatially and temporally associated with the 
recruitment of actin to the site of EB invasion, being considered an immediate early effector involved in the 
invasion and re-organization of the host cell cytoskeleton (Brinkworth et al., 2011; Clifton et al., 2004; Pais 
et al., 2013). TARP is present in all pathogenic Chlamydiae examined to date, but only in Ctr serovars is 
phosphorylated, ranging the number of phosphorylation sites between serovars (Clifton et al., 2004; 
Engel, 2004; Jewett et al., 2008, 2006). TARP is directly associated with actin, and this interaction 
promotes actin nucleation and recruitment, initiating the remodeling of the actin cytoskeleton. This 
remodeling can be done by stimulating cell signaling, activating the host actin-nucleating Arp2/3 complex, 
which is crucial for Ctr survival on the host (Brinkworth et al., 2011). TARP also seems to mediate the 
resistance to pro-apoptotic stimuli upon host cells during the early stages of infection (Mehlitz et al., 2010).  
The secretion of some T3S chlamydial substrates requires, in the bacterial cytosol, the assistance 
of chaperon proteins. Although various chlamydial substrates are reported, not so many T3S chaperones 
that bind to the effectors are. Recognition by the chaperons is done through a secretion signal—a short 
sequence of amino acids located at the beginning (the N-terminus) of the protein (usually within the first 
50 amino acids), that the needle complex is able to recognize (Löwer and Schneider, 2009). Chaperon 
proteins stabilize the chlamydial effectors maintaining the effectors in a translocation-competent 
conformation to pass through the T3SS. In 2011, Brinkworth and colleagues reported that Slc1 (CT043) is 
the chaperon for TARP and based on the information reported by Clifton et al, the first 200 aminoacids in 
the N-terminal part of TARP are enough for secretion being consider the binding site for the chaperon 
(Brinkworth et al., 2011; Clifton et al., 2005, 2004). In 2013, Pais and colleagues, reported that Slc1 is also 
the chaperon of CT694 and CT695 and that the first 100 aminoacids of N-terminal region of TARP are 
necessary and sufficient for the binding of TARP to the chaperon (Pais et al., 2013).  
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D. Chlamydial Genome 
Chlamydia trachomatis has a gene expression program consisting of early-genes (1-8h), mid-
genes (8-16h) and late-genes (16-24h) which coordinate the transition between the chlamydial 
developmental forms and the synthesis of virulence factors (Valdivia, 2008) . Ctr has a genome that 
consists of 1,042,519 nucleotide base pairs and has approximately 894 likely protein coding sequences 
(CDS) (Stephens et al., 1998). Most isolates of Ctr carry an extrachromosomal 7.5 kb plasmid which 
encodes eight CDS, arranged in a way that all but one of the genes are transcribed in the same direction. 
Assignment of biological functions has not been successful due to the absence of a simple mean to 
manipulate the chlamydial genome. Nonetheless, bioinformatic analyses have indicated that CDS1–CDS3 
are probably involved in plasmid replication; CDS3 may be involved in encoding an enzyme involved in 
unwinding DNA during replication; CDS7 and CDS8 display sequence homology with other plasmid 
partition proteins and thus are likely to be essential for plasmid maintenance (Wang et al., 2013a, 2011).  
Regarding the T3SS, 5-8% of chlamydial genome encodes targets of TTS and the genes are 
grouped in at least 4, and probably more, subclusters (Subtil et al., 2000; Valdivia, 2008). 
 
E. Chlamydia-host interactions  
Due to the small size of chlamydial genomes (<2Mb) with few repetitive elements and 
pseudogenes; many of the genes required for the biosynthesis of key metabolites have been lost and 
these are directly acquired from the host cell. This shows a strict dependence on the host for survival. 
These mechanisms allow the import and incorporation of nucleotides, amino-acids, lipids, iron and other 
essential host-derived nutrients from the host cell, while limiting detection by the innate immune system 
(Bastidas et al., 2013; Saka and Valdivia, 2010). It was also described that integration with multivesicular 
bodies (MVB), the Golgi apparatus, mitochondria and lipid droplets are required for optimal chlamydial 
replication (Saka and Valdivia, 2010). 
Due to the importance of the host survival, Chlamydia prevents host cell apoptosis through a 
variety of mechanisms (Mehlitz et al., 2010). Chlamydia uses a wide range of strategies that may subvert 
the host-immune responses, by interfering with the function of transcription factor NF-KB (a central 
regulator of immune response), blocking the phosphorylation/ubiquitination/degradation of IkB so the NF-
KB does not go into the nucleus in order to block the expression of hundreds of genes, including innate 
immune response factors (Lad et al., 2007). Chlamydiae has also developed a mechanism to limit the 
recognition of PAMPs (Pathogen-associated molecular patterns) by ensuring the stability of the inclusion 
during the intracellular stages of infection (Kumar and Valdivia, 2008). Also, Chlamydiae infection leads to 
stabilization of IAP2 (inhibitor of apoptosis protein 2) and up-regulation of the pro-survival factor Mcl-1 
(myeloid cell leukemia) (Rajalingam et al., 2008, 2006; Sharma et al., 2011). Infections can also activate 
MAPK (Mitogen-activated protein kinases) and PI3K (Phosphoinositide 3-kinase) pro-survival signaling 
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pathways which affect the bacterial nutrient acquisition, expression of antibiotic factors and synthesis of 
pro-inflammatory cytokines, such as the production of the inflammatory chemokine IL-8 (Interleukin-8) 
(Buchholz and Stephens, 2007; Rajalingam et al., 2008; Su et al., 2004). Moreover, Chlamydiae escapes 
the host defense mechanisms by preventing the fusion of the inclusion with acidic degradative 
compartments of the host cell, the fusion with lysosomes (Moulder, 1997; Subtil et al., 2001). Hackstadt 
and colleagues proposed that Chlamydiae meet these requirements by removing themselves from the 
endocytic pathway, by actively modifying the vacuole to become fusogenic with sphingomyelin-containing 
exocytic vesicles and not with lysosomes. Otherwise, that will lead to their eventual destruction in 
secondary lysosomes (Hackstadt et al., 1997). All these characteristics, among others, have a major 
impact on the survival of the host cell by avoidance of cell death and promoting self-survival (Bastidas et 
al., 2013). 
 
 
2. Chlamydia trachomatis genome manipulation 
The discovery of the DNA structure, its role and, as well, the knowledge of the genetic code had 
lead the discovery and efforts to the development of diverse genetic tools to work and handle DNA. This 
expertise is essential for a whole range of scientific and technological studies (Lodge et al., 2007). 
Ctr was for a long time reported as refractory to transformation and although the very limited 
genetic exchange that Chlamydia goes, there was also a huge lack of genetic approaches to manipulate 
the genome of this bacteria (Bastidas et al., 2013; Mehlitz et al., 2010; Skilton et al., 2009; Subtil et al., 
2001, 2000; Wang et al., 2013a). In 2009, an approach using chromosomal integration was used to make 
recombinants in Chlamydia psittaci EBs by allelic exchange using exogenous DNA introduced by 
electroporation (Binet and Maurelli, 2009). In 2011 some developments were made to mutate the 
chlamydial chromosome (Kari et al., 2011). Nonetheless a demand for development of a simple robust 
genetic transformation system for the Chlamydiae has remained a significant challenge (Wang et al., 
2011). 
In 2011, Wang and coworkers reported for the first time a successful, simple and robust plasmid-
based genetic transformation system for Chlamydia trachomatis serovar L2 (Ctr L2) using penicillin 
selection and calcium chloride (CaCl2) treatment of EBs. Wang and colleagues were able to produce a 
strain of Ctr L2 that is penicillin resistant and shows similar growth characteristics and inclusion formation 
as the WT (Wild Type) strain (Wang et al., 2011). 
The ability to genetically manipulate Chlamydiae is a complementary advancement that will 
enhance the understanding of chlamydial pathogenesis; accelerating the development of new anti-
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chlamydial therapeutic control measures, chlamydial vaccines and therapeutic interventions (Kari et al., 
2011; Wang et al., 2011). 
 
 
3. Genetic lineage tracing mediated by CRE recombinase  
There are increasing evidences that some bacteria can contribute to specific stages in cancer 
development, particularly in chronic infections (Mager, 2006). These pathogens can be involved in the 
hypothesis that bacterial molecules are necessary for the initiation but not the maintenance of cellular 
transformation (Kuper et al., 2000). Therefore, identification of the damaged cells that have been in 
contact with the pathogen of interest could help to determine and describe the link between the pathogen 
and further transformations, like cancer (Lax and Thomas, 2002).  
The cyclisation recombination (CRE) enzyme of bacteriophage P1, a 38 kDa site-specific 
recombinase was first developed as an in vivo molecular tool over two decades ago. CRE recombinase 
catalyzes recombination between its recognition sites (LoxP sites) in any cellular environment and on any 
kind of DNA. The LoxP sites consist of a consensus 34 base pairs DNA and a sequence of 8bp and 13bp 
palindromic flanking sequences. At least two LoxP sites are need for the CRE recombinase activity to 
occur (Guo et al., 1997; Nagy, 2000; Smith, 2011; Stricklett et al., 1999).  
Inducible CRE cell lines are increasing in popularity due to the ability for elegant temporal, 
mutually exclusive and spatial targeting of genes. The development of CRE/LoxP has expanded and 
refined the toolbox of genetic manipulation available to researchers and there are now more than 500 
independent CRE recombinase expressing mouse lines, many of which are accessed via CREXmice 
database (Muzumdar et al., 2007; Nagy et al., 2009; Smith, 2011). Since its initial use, several improved 
versions of CRE have been developed, which utilize eukaryotic codon preference to improve the 
expression of CRE, such as iCRE (Shimshek et al., 2002) or the addition of a eukaryotic nuclear 
localization signal to increase recombination efficiency (Kalderon et al., 1984). 
In 2007, Muzumdar and colleagues described a double fluorescent CRE recombinase reporter 
mouse. In this system (see Figure I.3) if CRE interacts with a mT/mG construct, that expresses tdTomato 
(mT) prior to CRE excision and membrane-target GFP (mG) after CRE excision, this will allow the live 
visualization and distinction of recombined and non-recombined cells, enabling bright fluorescent labeling 
of all tissues/cells: red before and green after CRE recombination. Additionally, the double fluorescent 
membrane targeted system permits tracing of lineage and characterization of cell morphology in vivo 
(Muzumdar et al., 2007). Livet and coworkers explored the advantages of the widely used CRE/LoxP 
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recombination system, which can switch on gene expression by DNA excision, inversion or 
interchromossomal recombination (Livet et al., 2007). 
 
 
Figure I.3 The CRE/LoxP recombination system. Schematic example of CRE recombinase activity 
in a mT/mG reporter cell. mT/mG consists of a chicken bactin core promoter with a CMV enhancer (pCA) driving 
a loxP flanked coding sequence of membrane-targeted tandem dímer Tomato (mT) resulting in tdTomato expression 
with membrane localization. When CRE enters the reporter cell line the mT gene is excised due to CRE 
recombination activity and the reporter cell line becomes green instead of the red fluorescence. Arrows denote the 
direction of transcription. Triangles - LoxP target sites for Cre-mediated recombination. PA - polyadenylation 
sequences (Muzumdar et al., 2007). 
 
Another modification of this system, described by Hirrlinger and coworkers is the introduction of a 
second dimension to cell-type specific control of DNA-recombination in vivo, the Split-CRE. They divided 
the CRE recombinase into two fragments and fused both to strong protein interaction domains. The 
resulting fusion proteins (NCRE and CCRE) were able to complement each other thus reconstituting 
functional CRE recombinase in neurons and glia of a living mouse. Split-CRE allows selective genetic 
targeting of cell populations defined by the simultaneous activity of two promoters in the mouse (Hirrlinger 
et al., 2009b). 
The advantages of the CRE/LoxP recombination system are the no need for additional co-factors 
or sequence elements for efficient recombination regardless of the cellular environment. LoxP target sites 
are small and easily synthesized, there are no apparent external energy requirements and CRE is a stable 
protein (Nagy, 2000; Stricklett et al., 1999). Application of this technology to the mammalian system is 
possible because the mammalian genome lacks high affinity LoxP sites, therefore, artificially engineering 
these specific sequences into DNA regions flanking a target locus of interest for recombination by CRE 
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recombinase is a major gain to any genetic engineer system (Smith, 2011). CRE recombinase has several 
important applications as: (1) a traditional targeting and selectable marker removal; (2) CRE excision 
conditional gene knock-out; (3) CRE excision conditional gene repair; (4) it can be used as well in a 
combination with an inducible system by the use of tamoxifen, for instance; between many other 
promising applications (Nagy, 2000). As for Split-CRE, the complementation can be broadly applied and is 
independent of the expression method as well as the cellular context (Hirrlinger et al., 2009b). 
Despite the enormous success of cell-specific gene targeting using Cre/LoxP, two major 
limitations are inherent to this system: (1) the time of recombination is solely determined by the time of 
onset of the promoter activity driving CRE expression and cannot be controlled experimentally; (2) the 
specificity of the promoter used to drive CRE expression is often not sufficient to selectively target a 
specific cell population (Hirrlinger et al., 2009a). On the other hand, CRE recombinase is certainly one of 
the key tools that made many of the newly developed genome alteration technologies possible (Nagy, 
2000). 
 
 
4. Aims 
The aim of this project is to generate a genetically modified Ctr that is able to label the host cell 
following the infection. The label is permanent so that both, cells with ongoing infection and cells that 
survived after an infection, can be detected, isolated and characterized. With this tool is possible to 
monitor if cells are surviving the infection or not. Moreover, since it has been demonstrated that Ctr 
induces DNA damage in the host cell, this tool can be used to track cells that might have undergone 
cellular transformation directly triggered by the pathogen. This labeling system is based on a ―signal‖ that 
is provided by the pathogen and on a ―sensor‖ that is located in the host cell. The triggering ―signal‖ is the 
CRE recombinase enzyme. CRE is bound to a translocated protein that is delivering the ―signal‖ into the 
host cell. The ―sensor‖ is based on a genetic reporter that changes permanently the expression of the 
fluorescent gene upon CRE recombination (red to green). In order to generate a genetically modified Ctr, 
a previously published transformation protocol was established. 
Therefore, the present study was divided into three steps: (1) generation of a plasmid coding a 
chlamydial protein (TARP) fused with CRE for translocation via T3SS; (2) transformation of Ctr with the 
generated plasmid and (3) test the functionality of the system into a stable reporter cell line sensitive to 
CRE activity (HeLa229_mT/mG). This process should lead to an irreversible label that will allow the 
detection of cells which were at any time infected with Ctr. The establishment of such a system is a 
significant launch on further longer projects.  
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II. Materials  
In Table II.1 to Table II.7 the reagents, solutions, antibodies, growth media, commercial kits, 
restriction enzymes and commercial plasmids, included in this study are enumerated by manufacturer and 
lot number. 
Table II.1 Expendable reagents  
Manufacturer Reagents 
Applichen 
Tris ultrapure (Art. Nr: A1086.5000; Lot. 2Z002392); Bromophenol blue 
(Art. Nr: A233.0005; Lot. 9Q005789); Non-fat dried milk (Art. Nr: 
A08301000; Lot.20003941) 
Bacto Bacto yeast extract (Art. Nr: 212720; Lot.8023617) 
Biochrom Fetal Calf Serum - FCS (Art. Nr: S0115; Lot. 0710x) 
Biomol 
Albumin bovine (BSA) fraction V (Art. Nr: 01400.1; Lot. 1740); Glycine p.A. 
Aminoacetic acid (Art. Nr. 04943.2500: Lot.7844) 
Carl Roth 
NaOH (Art. Nr: P031.2; Lot. 2151855); X-gal (Art. Nr: 2315.3; Lot. 
2306408); EDTA (Art. Nr: 8043.2; Lot. 2053583); Triton-X-100 (Art.Nr: 
3051.2); Calcium Chloride (Art. Nr: A119.1; Lot.350158003); LB-Agar (Art. 
Nr: X965.2; Lot.250156129); X-Gal (Art. Nr: 2513.3); TEMED (Art. Nr: 
2367.3; Lot. 2037446); Retiphorese Gel 30 (30% Acrylamid) (Art. Nr: 
3029.1; Lot. 221172398); β-Mercaptoethanol (Art. Nr: 4227.1; Lot. 
2004646); Glycerin (Art. Nr: 4043.3; Lot. 36790090); NaCl (Art. Nr: 9265.2; 
Lot.073196636) 
Fisher Scientific 
Ethidium bromide solution (Art. Nr: E/P800/10; Lot. 09255985); Tryptone 
(Art. Nr: BP1421500) 
Gibco 
DPBS (Art. Nr: 8043.2; Lot. 1479939/1525810/1532363); Trypsin (Art. Nr: 
25300-096; Lot. 1401952/1508836/1550252); L-Glutamine (Art. Nr: 25030-
024; Lot. 1437728) 
Invitrogen LB Broth Base (Art. Nr: 12780052; Lot.00810292) 
Merck  
Tween 20 (Art. Nr: 8.22184; Lot.); APS - Ammonium Persulfate (Art. Nr: 
K36015201707; Lot.1.01201.0500); Acetic Acid (Art. Nr: K40866663009; 
Lot.1.00063.2500); Methanol (Art. Nr: 1714009344; Lot.1.06009.2511); 
Isopropanol (Art. Nr: K43800534237; Lot.1.09634.2511); Ethanol (Art. Nr: 
K45251683403; Lot.1.00983.2511); Methylene Blue (C.I. 52015) (Art. Nr: 
159270); Glucose (Art. Nr: K38076537806; Lot. 1.08337.1000); MgSO4 
(Art. N: 1.05886; Lot.A963086) 
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Sigma – Aldrich 
Ampicillin (Art. Nr: A9518-1006; Lot. 074K0522); DAPI - bisBenzimide 
H33342 trihydrochioride (Art. Nr: B2261-100MG; Lot.116K4029); Mowiol 
(Art. Nr: 32,459-0); Paraformaldehyde (Art. Nr: 441244-1kg; 
Lot.MKBK8362V); Penicillin G + Sodium salt (Art. Nr: P3032-100MU; 
Lot.SLBC7349V); Tween-20 (Art. Nr: S6536884235; Lot.8.22184.0500); 
KCl (Art Nr: P9541); Cycloheximide (Art. Nr: C1988-1G; Lot.065K122261); 
Boric Acid (Art. Nr: B0252; Lot.57H0655); Magnesium chloride (Art. Nr: 
M2393-100G; Lot. 064K0110); Na-Pyruvate (Art. Nr: S8636; Lot. 
RNB07806) 
Serva SDS (Art. Nr: 20765.03; Lot.120895) 
Thermo Scientific 
Draq5 (5mM) (Art. Nr: 62252; Lot.316Dr51000): IPTG dioxiane free (Art. 
Nr: R0391; Lot. 99131); FastAP (Art. Nr: EF0654; Lot.00152428); FastAP 
Buffer 10x (Lot.00149725); 1kb DNA Ladder (Art. Nr: SM0311); 50bp DNA 
Ladder (Art. Nr: SM0371); Protein Ladder (Art. Nr: SM1812)  
 
 
 
Table II.2 Solutions and Buffers 
Solution/Media Composition 
Blocking Buffer for 
Immunofluorescence 
BSA 0.5% (w/v), Tween 20 0.05%(w/v), PBS 1X 
EDTA  0.5 M disodium ethylenediamine tetraacetate (pH8.0) 
Lysis Buffer 25 mM EDTA, 5 mM Tris, 10% SDS, 20 mg/ml Proteinase k 
SDS-PAGE Running Buffer (10x) 25 mM Tris, 192 mM glycine, 0.1% (w/v) SDS  
SDS-PAGE Sample buffer (2x) 
62.5 mM Tris-HCl pH 6.8; 10% (w/v) Glycerol, 2.5% (w/v) SDS, 
0.002% (w/v) Bromophenol blue.  
SDS-PAGE Transfer Buffer 25 mM Tris-Base, 192 mM Glycine, 20% (w/v) methanol (pH 8.3) 
SPG buffer (Sucrose-Phosphate-
Glutamic acid) 
220 mM Sucrose, 3 mM KH2PO4, 8 mM Na2HPO4, 5 mM L-
Glutamic acid (pH 7.4)  
TAE Buffer 50x 40 mM Tris, 20 mM acetic acid, 1 mM EDTA (pH 8.0) 
TBE Buffer 89.15 mM Tris/HCl, 88.95 mM Boric acid, 2 mM EDTA  
TBS 1x 50 mM Tris-Cl with pH 7.6, 150 mM NaCl 
TE Buffer 10 mM Tris-Cl, 1 mM EDTA (pH 8.0) 
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Table II.3 Antibodies 
Antigen Specie Dilution for IF Dilution for WB Company 
Primary Antibodies 
Anti-Chlamydia MOMP Mouse 1:10000 - 
University of Washington 
(Lot.90813) 
Anti-CRE recombinase Mouse - 1:1000 Abcam (Art N: Ab24607) 
Anti-ß-Catenin Rabbit 1:100 - Sigma (Art N: C2206) 
Secondary Antibodies 
ECL Anti-Mouse IgG Sheep - 1:3000 
Amersham NA931-1ml 
(Lot. 9471753) 
Cy2 Anti-Mouse IgG Goat 1:200 - Dianova (Lot.78409) 
Cy2 Anti-Mouse IgG Donkey 1:100 - 
Dianova (Art. Nr: 715-225-
151; Lot. 86595) 
Cy2 Anti-Rabbit IgG Goat 1:150 - Dianova (Lot.81780) 
 
 
Table II.4 Growth media and its composition 
Manufacturer Growth Media 
Gibco 
DMEM 1x (Art. Nr:10938-025; Lot.1450389/1482361/1485850) 
MEM 1x (Art. Nr:51200-046; Lot.1482357) 
RPMI 1640 1x (Art. Nr:52400-025; Lot.1437700/1528246/1437700) 
 
 
Table II.5 Commercial kits 
Manufacturer  Kit  
Qiagen 
QIAquick PCR Purification Kit (Art. Nr: 28106) 
QIAquick Gel Extraction Kit (Art. Nr: 28706) 
QIAprep Spin Miniprep Kit (Art. Nr: 27106) 
Qiagen Plasmid Midi Kit (Art. Nr: 12145) 
QIAfilter Spin Maxiprep Kit (Art. Nr: 12263) 
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Table II.6 Restriction enzymes 
Manufacturer Enzyme Buffer 
Thermo Scientific 
KpnI (Art. Nr: #FD0524) 
FD Green Buffer (Art. Nr: #B72; 
Lot.133213) 
FD Buffer (Art. Nr: #B64; 
Lot.00151181) 
EagI (Art. Nr: #FD0334) 
NheI (Art. Nr: #FD0974) 
ApaI (Art. Nr: #FD1414) 
ScaI (Art. Nr: #FD0434) 
DpnI (Art. Nr: #FD1703) 
BamHI (Art. Nr: #FD0055) 
ScaI (Art. Nr: #FD0434) 
PvuI (Art. Nr: #FD0624) 
EcoRII (Art. Nr: #ER1921) Orange Buffer 
(Art. Nr: #B05; Lot.00183458) 
New England Biolabs 
SacII (Art. Nr:#R3122) Cut Smart Buffer (Art. Nr: 
B72045; Lot.0041305) NheI (Art. Nr:#R3131) 
 
 
Table II.7 Commercial plasmids 
Origin Plasmid ID 
Addgene  p_101AATARP-CRE1916: pBS185 CMV-CRE 
Promega pGEM®-T Easy Vector (Art. Nr.: A1360: Lot 0059768) 
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III. Methods  
1. Cell culture and bacterial strains 
HeLa and McCoy cells lines (Table III.1) were cultured in growth medium at 37°C in a cell culture 
incubator under humidified atmosphere containing 5% CO2. Before passaging, adherent cells were 
washed once with PBS (Invitrogen) and 1 ml of Trypsin (0.05%)-EDTA, trypsin as a protease to hydrolase 
proteins for cell dissociation and EDTA used as a chelating agent that binds to calcium and prevents 
clumping of cells, were added per 75 cm3 culture flask and cells were incubated approximately 3 min at 
37°C until they detached. Cells were resuspended in growth medium and transferred into fresh culture 
flasks in a 1:4 dilution. Cells were maintained in culture and split every two or three days to avoid 
complete confluence. 
Table III.1 Cell lines used 
Cell Line Cultured in 
HeLa229 
Homo sapiens, cervix, epithelial 
(ATCC CCL-2.1) 
RPMI 1640 medium with 2 mM L-glutamine and 25 mM 
HEPES (Invitrogen), 10% FCS, heat-inactivated 
(Biochrome). 
HeLa229_mT/mG 
Homo sapiens, cervix, epithelial 
 (Toelle et al., unpublished)  
RPMI 1640 medium with 2 mM L-glutamine and 25 mM 
HEPES (Invitrogen), 10% FCS, heat-inactivated 
(Biochrome). 
McCoy cells 
Mus musculus, fibroblast  
(ATCC CRL-1696) 
DMEM medium with 10% FCS, 25 mM HEPES 
(Invitrogen), 1 mM Na-Pyruvate, 2 mM L-glutamine and 
10% FCS, heat-inactivated (Biochrome). 
  
HeLa229_mT/mG (reporter cell line) is an in-house constructed from HeLa cell line, based on the 
cell line described by Muzumdar and colleagues (2007). They were transduced with a construct (pLenti-
mTmG – 12807bp) under CAG promoter, making the cells susceptible to a CRE recombinase-induced 
switching from red fluorescence to green fluorescence. Afterwards, these cells were selected for 
puromycin resistance and sorted via FACS for stable expression of membrane tagged tdTomato (mT) 
(unpublished).  
Four different bacterial strains were used in this work, (Table III.2 and Table III.3) with different 
applications. Chlamydia trachomatis serovar D and L2 were used for infection of the cell lines described in 
Table III.1 and for transformation. Ctr L2 elementary bodies (EBs) were purified from infected HeLa229 
cells. Two E. coli strains were used as competent cells for achievement of clones with the constructed 
plasmids (Table III.3).  
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Table III.2 Bacterial strains used for infection and transformation 
Strain Origin 
Chlamydia trachomatis Serovar D Human cervix (UW-3/Cx ATCC VR-885) 
Chlamydia trachomatis Serovar L2 Lymphatic isolate (L2/434/Bu ATCC VR-902B) 
 
Table III.3 Bacterial strains used for the cloning 
Strain Genotype Origin 
Escherichia coli 
TOP10F‗ 
F'[lacIqTn10(tetR)]mcrAΔ(mrr-hdRMS-
mcrBC)φ80lacZΔM15ΔlacX74deoRnupGrecA1araD139 
Δ(ara-leu)7697galUgalKrpsL(StrR)endA1λ- 
Invitrogen 
(pHuLUC3/TOP10 
ATCC PTA-10989) 
Escherichia coli 
JM110 
rpsL (Strr)thr leu thi-1 lacY galK galT ara tonA tsx dam 
dcm supE44∆(lac-proAB) [FtraD36proABlacIqZ∆M15] 
Stratagene 
(pBMS2000-PPFOH-
PDHmod  
ATCC PTA-4520) 
 
2. Software for data analysis 
During this work several software packages were used for different purposes: Clone Manager 9 to 
plan the cloning; Image J, Photoshop CS5, VisiView, ScanR (Olympus) for acquirement and treatment of 
photos and images; CorelDRAWX4 for the design of schemes, Prism5 and Microsoft Excel for data 
analysis. 
 
3. Bacterial DNA extraction 
Chlamydia trachomatis DNA was extracted using the phenol/chloroform method. Gram negative 
bacteria (1x10
8
 CFU) were resuspended in lysis buffer and then incubate 1 h at 37°C. 
Phenol/chloroform/isoamyl alcohol (1:1) was added and the phases were mixed by repeatedly inversion of 
the tube. The sample was spun-down at maximum speed and a white layer (protein layer) is visible at the 
aqueous:phenol/chloroform interface. The upper aqueous phase was transferred carefully to a new tube. 
To remove the phenol, an equal volume of chloroform was added to the aqueous layer and the sample 
was spun-down again at maximum speed for 5min. The aqueous layer was transferred to a new tube. To 
precipitate the DNA, ETOH was added and mixed gently. After 30 min Incubation at -20°C for the sample 
and spun down at maximum speed for 15 min at 4°C. The supernatant was discarded and the DNA pellet 
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was rinsed with 70% ethanol and spun-at maximum speed. The supernatant was carefully discarded, the 
DNA pellet was air-dried and resuspended in TE buffer. 
 
4. Chlamydia trachomatis infection 
HeLa or McCoy cells (Table III.1) were infected, with different MOI‘s (1, 2, 5 and 10) of Ctr L2 and 
Ctr D, 24 h after the seeding in RPMI or in DMEM supplemented with 5% FCS (Infection Medium), and 
incubated for 2 h. 2 h.p.i. fresh medium was added and the infected cells were incubated for 2 d (in case 
of Ctr L2) or 3 d (in case of Ctr D). 
 
5. Immunofluorescence staining 
For fixation, permeabilization and blocking two methods were applied, depending on the 
antibodies used: (1) the infected cells were fixed and permeabilized with ice-cold methanol and incubated 
overnight at 4°C and later blocked with 0.5% BSA in PBS for 30 min at RT or (2) the infected cells were 
fixed with 3,7% paraformaldehyde for 10 min and permeabilized and blocked with 0.5% BSA-0.02% 
Tween-20/Triton X-100 in PBS for 30 min at RT. The primary antibody was added at the recommended 
dilution in blocking solution for 1 h at RT, followed by three washing steps with PBS. The secondary 
antibody was added at the recommended dilution together with Hoechst (1:1000 dilution) for host nuclei 
staining, diluted in blocking solution and incubated for 1 h in dark at room temperature followed by three 
washing steps with PBS. Finally PBS was added and the plates were analyzed by fluorescence or 
confocal microscopy.  
 
 
6. Genetic transformation of Chlamydia trachomatis serovar D and L2 
Plasmid DNA was prepared from a methylation deficient strain, E. coli JM110, dam
-
dcm
-
, strain 
using the Qiagen Plasmid MidiKit, as indicated by the manufacturer. The infected McCoy cells were 
cultured in DMEM supplemented with 10% heat inactivated FCS (Table III.1). The following protocol was 
adapted from procedures developed by Wang and colleagues (Wang et al., 2013a, 2013b, 2011); Agaisse 
and Derré (Agaisse and Derré, 2013); Song and colleagues (Song et al., 2013) and Bauler and Hackstadt 
(Bauler and Hackstadt, 2014). 
For transformation of Ctr D and L2: a solution with 50 µl of stock 2.3x10
9
 Chlamydia trachomatis D 
EBs, 12 µg plasmid DNA and 200 µl CaCl2 buffer was prepared and incubated for 30 min at room 
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temperature. Subsequently, antibiotic free medium was added and the bacteria added on McCoy 
monolayer in 6-well plates. The infected cells were centrifuged at 2400 rpm for 30 min (Thermo scientific 
Multifuge 3S-R Heraus) and allowed to settle at 35°C in 5%CO2 for 2/3 days without cycloheximide or 
penicillin G treatment. 48 h.p.i. (for Ctr L2) or 72 h.p.i. (in case of Ctr D), the cells were detached using a 
24 cm cell scarper (TPP #99002) and disrupted by vortexing using 3 mm glass beads (Roth, ArtA557.1 
Lot.290159680) for 3 min. The cell debris were discarded by centrifuging 5 min at 1500 rpm (Eppendorf 
Centrifuge 5804R) and the cell suspensions were added to a new cell monolayer. In case of, Ctr serovar 
D the flasks were centrifuged at 2100 rpm for 15 min at 4º C (Beckman Coulter Allegra 6R Centrifuge), 
and allowed to settle. After 2 h, the medium was changed to new infection medium (DMEM medium with 
5% heat-inactivated FCS, 25mM HEPES (Invitrogen), 1 mM Na-Pyruvate, 2 mM L) with penicillin G 
selection and 1 µg/ml of cycloheximide (Sigma) for McCoy cells and/or for HeLa cells as well (RPMI 1640 
medium with 2 mM L-glutamine and 25 mM HEPES (Invitrogen), 5% heat inactivated FCS) with penicillin 
G selection and 1 µg/ml of cycloheximide (Sigma). At Passage 4, one T25 cm
3
 flask lysate from McCoy 
cells was added to a HeLa229 cell monolayer and vice-versa. The cultures were then selected with 
penicillin G during passages, as described in Table III.4 and Figure III.1. 
 
 
Figure III.1 Methodology adopted for Chlamydia trachomatis serovar L2 (Ctr L2) genetic 
transformation. In the case of Ctr D, the days were adapted to its life cycle as shown in Table III.4. 
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Table III.4 Transformation of Chlamydia trachomatis serovar D and L2. Information relative to every 
passage of transformation of Chlamydia trachomatis serovar D and L2. 
Passage Culture vessel 
Penicillin G 
selection 
Duration 
Passage 1 
(the content of the three 
wells is used) 
T150 flask of McCoy 
0.1 units/m 
(±0.006µg penG) 
2 d for Ctr L2 
3 d for Ctr D 
Passage 2 
(use half of the T1 to 
each flask) 
T25 flasks 
(one with HeLa and other with McCoy) 
0.1 units/ml 
(±0.006µg penG) 
3 d for Ctr L2 
4 d for Ctr D 
Passage 3 
(use T2 ) 
T25 flasks 
(one with HeLa and other with McCoy) 
0.1 units/ml 
(±0.006µg penG) 
2 d for Ctr L2 
3 d for Ctr D 
Passage 4 
(use T3 ) 
T25 flasks 
(one with HeLa and other with McCoy) 
0.1 units/ml 
(±0.006µg penG) 
2 d for Ctr L2 
3 d for Ctr D 
Passage 5 
(use T4 ) 
T25 flasks 
(one with HeLa and other with McCoy) 
0.1 units/ml 
(±0.006µg penG) 
2 d for Ctr L2 
3 d for Ctr D 
Passage 6 
(use T5 ) 
T25 flasks 
(one with HeLa and other with McCoy) 
1 units/ml 
(±0.06µg penG) 
2 d for Ctr L2 
3 d for Ctr D 
Passage 7 
(use T6 ) 
T25 flasks 
(one with HeLa and other with McCoy) 
2 units/ml 
(±0.012µg penG) 
2 d for Ctr L2 
3 d for Ctr D 
 
After Passage 7 the infection was propagated with increasing concentrations of penicillin G; for 
further preparation of transformed Chlamydia trachomatis stock. 
 
7. Propagation and preparation of the chlamydial stock 
For the preparation of Ctr stocks, Ctr were propagated in HeLa cells in T150 cm
3
 cell culture 
flasks with 25 ml of growth medium. Cells were infected with lysates from earlier passages and incubated 
at 35°C in a cell culture incubator under humidified atmosphere with 5% CO2 until time of harvest. 48 
h.p.i., the cells were detached using a 24cm cell scarper (TPP #99002) and disrupted by vortexing using 3 
mm glass beads (Roth, ArtA557.1 Lot.290159680) for 3 min. The cell suspensions were centrifuged at 
1500 rpm at 4°C for 10 min (Eppendorf Centrifuge 5804R). The resulting supernatant was collected and 
centrifuged at 20000 rcf for 40 min at 4°C in a SS-34 rotor (Sorval RC 5C Plus) to pellet Chlamydia EBs. 
The harvested bacteria were resuspended in 5 ml of SPG buffer (4º C). A second centrifugation was 
performed and the pellet resuspended in 4 mL of SPG buffer (4º C). To dissolve any clumps, a G-23, a G-
27 and lastly a G-30 gauge injection needles were used. Chlamydia suspensions were aliquoted and 
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frozen at -80°C. Before each experiment Chlamydia was freshly thawed. Presence of Mycoplasma spp. 
was excluded using the VenorGeM PCR assay.  
To determine the infectivity of purified Ctr stock, serial dilutions of freshly thawed bacteria were 
prepared in infection medium wit 50 μl per well of each dilution inoculated into a 96F-well plate containing 
HeLa cells seeded one day before (5000 cells/well). 2 h.p.i. at 5% CO2 and 37°C, the infection medium 
was replaced with 100 μl per well of fresh infection medium and incubated again under similar conditions. 
After 24 h, the cells were fixed, permeabilized and stained with the DAPI. The average number of 
inclusions per cell was determined for each dilution. The dilution of bacteria leading to the formation of 
one inclusion per cell upon infection was calculated and considered to have an MOI of 1. 
 
8. Gene Cloning 
Gene cloning is the use of a fragment of DNA from an organism where it naturally occurs, and 
putting it into a cloning host such as the bacterium Escherichia coli, even when subsequently it will be 
used to be transferred into another organism. It is necessary to clone the fragment of DNA into a proper 
cloning vector, with the right promoter that will be copied every time that the cell copies its own DNA. On 
this cloning vector, a plasmid, the fragment of DNA is inserted after cutting it using restriction enzymes 
and later ligation by DNA ligase. The ligation reaction efficiency can be increased by treating the cut 
vector in such a way that the two ends cannot be ligated to each other, but can still be ligated with an 
insert, by the treatment of the vector with alkaline phosphatase, removing the 5′ phosphates from the cut 
vector preventing it to ligate with itself (Lodge et al., 2007). 
 
A. DNA Manipulations, Plasmids and Primers 
The main plasmids used and generated in this work and their main features are detailed in Table 
III.5 and the primers used are shown in Table III.6. Plasmids were constructed using standard DNA 
manipulations with proof-reading Phusion High Fidelity DNA polymerase (NEB #M053OS), restriction 
enzymes (Table II.6), T4 DNA Ligase (NEB and Promega), QIAquick PCR Purification Kit and Gel 
extraction kit (Qiagen), and the DNA extracted with the Plasmid Mini/Midi/Maxiprep kit (Qiagen and 
Thermo Scientific), according to the instructions of each manufacturer. Ctr genes, or parts of genes, were 
amplified by PCR from genomic DNA of strain L2/434 using custom oligonucleotide primers, Table III.6. 
The accuracy of the nucleotide sequence of all the inserts of the constructed plasmids was checked by 
DNA sequencing (MWG) (Supplementary Data 1). 
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Table III.5 Constructed plasmids 
Plasmid ID Genetic elements Resistance Amplified in 
p2TK2-SW2_IncDProm-
mCherry-IncDTerm 
IncDProm-mCherry-IncDTerm             
IncD_Gene ID: 5859205 
Ampicillin E. coli JM110 
pGEM®-T Easy Vector-
TARP 
TARP_GeneID:884231 Ampicillin E. coli TOP10F‘ 
p2TK2-SW2_IncDProm-
IncDTerm 
IncDProm-IncDTerm             
IncD_Gene ID: 5859205 
Ampicillin E. coli TOP10F‘ 
 p_101AATARP-CRE 
IncDProm-IncDTerm 
IncD_Gene ID: 5859205  
101AATARP_Gene ID:471472  
CRE_Gene ID:10678 
Ampicillin E. coli JM110 
p_TARP-CRE 
IncDProm-IncDTerm 
IncD_Gene ID: 5859205 
TARP_Gene ID:471472 
CRE_Gene ID:10678 
Ampicillin E. coli JM110 
 
 
Table III.6 Primers used 
Primer Name Sequence 
1 
TARP from Chlamydia trachomatis L2 
FW 
CGGAGGAACCTTGGACAATA 
2 
TARP from Chlamydia trachomatis L2 
RV 
AGGGAGTGACCTGCTCTGAA 
3 IncDPromoter FW (KpnI-Prom-NheI)  GTTTCGCCACCTCTGACTTG 
4 IncDPromoter RV (KpnI-Prom-NheI)  
TCATCCCGGGCCCTAGACGCTAGCACCTCACTTC
GACAGATTTTAGC 
5 IncDTerminator FW (ApaI-Term-EagI)  GTCTAGGGCCCGGGATGACATGTGATTCGCGTAG 
6 IncDTerminator RV (ApaI-Term-EagI) TTGAAGCGCTCCGGATAGTG 
7 TARP FW (NheI-TARP-SacII-Linker)  GAGGCTAGCATGACGAATTCTATATCAGGTGATC 
8 
TARP 101AA RV (NheI-TARP-SacII-
Linker)  
AGGGTTGCTAGGGCTGGCCCGCGGTTTTCCAGCA
ACGGCTTGGG 
9 
TARP full RV (NheI-TARP-SacII-
Linker)  
CATCCGCGGTCCTACGGTATCAATCAGTG 
10 CRE FW (Linker-NaeI-CRE-ApaI) 
GCCAGCCCTAGCAACCCTGGCGCCAGCAACGGCA
GCGCCGGCATGCCCAAGAAGAAGAGGAAGG 
11 CRE RV (Linker-NaeI-CRE-ApaI)  GAGGGGCCCTCGACCTAATCGCCATCTTCC 
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B. Cloning plan for p_101AATARP-CRE and p_TARP-CRE 
The molecular cloning of p_101AATARP-CRE and p_TARP-CRE was designed first in silico using 
Clone Manager 9 software, the final cassette of each are presented in Figure III.2. The cloning was 
divided into three main steps in order to create two final plasmids ( p_101AATARP-CRE and p_TARP-
CRE), these two final plasmids will have the same backbone as the p2TK2-SW2_IncDProm-mCherry-
IncDTerm plasmid used (Table III.5) for establishing the protocol of transforming Ctr but instead of the 
mCherry protein, two recombinant TARP–CRE protein versions were inserted.  
 
 
 
Figure III.2 Final plasmids constructs (p_101AATARP-CRE and p_TARP-CRE) 
 
Part A: as summarized in Figure III.3, after the DNA extraction from Chlamydia trachomatis, TARP 
was amplified using primer 1 and 2 (Table III.6) and using the TA-cloning methodology (Promega Kit), 
TARP was inserted in pGEM®-T Easy Vector (Table III.5). From the p2TK2-SW2_IncDProm-mCherry-
IncDTerm plasmid (Table III.5) the IncDPromoter and IncDTerminator were amplified using primers 3-4 
and 5-6 respectively. The first overlap PCR was performed using the products from the PCR of 
IncDPromoter and IncDTerminator as templates. The IncDpromoter-mCherry-IncDTerminator was cut 
from the p2TK2-SW2_IncDProm-mCherry-IncDTerm plasmid using the restriction enzymes KpnI and EagI 
Ana da Costa Methods 
 
 
Page | 23  
and the product from the overlap PCR cloned inside creating the plasmid p2TK2-SW2_IncDProm-
IncDTerm (Table III.5). 
 
 
Figure III.3 Part A, resulting in the backbone plasmid p2TK2-SW2_IncDProm-IncDTerm. 
 
 
Part B: as shown in Figure III.4, the 101AA TARP was amplified by PCR (reaction A) from 
pGEM®-T Easy Vector-TARP (Table III.5) using primer 7 and 8 (Table III.6). CRE was generated by PCR 
(reaction B) from the pBS185 CMV-CRE plasmid (Table III.5) using primer 10 and 11. An overlap PCR 
was performed using the matching products from reaction A and B are, in part, complementary between 
them, creating a product that was cloned inside of the plasmid p2TK2-SW2_IncDProm-IncDTerm (Table 
III.5) using the restriction enzymes ApaI and NheI.  
Part C: finally to create p_TARP-CRE (Table III.5), as shown in Figure III.5, the full TARP was 
amplified by PCR from pGEM®-T Easy Vector-TARP (Table III.5) using Primer 7 and 9 (Table III.6) and 
the product was cloned into p_101AATARP-CRE using the restriction enzymes SacII and NheI (Table 
II.6). 
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Figure III.4 Part B resulting in p_101AATARP-CRE. 
 
 
 
Figure III.5 Part C resulting in p_TARP-CRE. 
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The next methodology points will present a more detailed procedure for the cloning of 
p_101AATARP-CRE and p_TARP-CRE: 
 
C. TA cloning  
TA Cloning consists on the treatment of the fragment with a Taq polymerase in the presence of 
dATP, adding a single non template-directed deoxyadenosine (dATP) residue to the 3' end of the PCR 
product; the vector is then tailed with dideoxythymidine triphosphate (dTTP). Thusly, it is created a 
complementary one base pair sticky ends because a ddT-tailed vector can ligate directly to a PCR product 
that contains a 3'-overhanging dATP by forming a phosphodiester bond between the vector's 5'-P and the 
PCR product's 3'-OH group from the overhanging adenosine (Holton and Graham, 1991; Marchuk et al., 
1991). The insert may be ligated to the T-vector in either direction; therefore TA cloning is ideal when both 
orientations of the insert DNA in the plasmid are required. This strategy is both simple and one hundred 
fold more efficient than blunt-ended ligation for the cloning of PCR products (Marchuk et al., 1991; Zhou 
and Gomez-sanchez, 2000).  
In this study, TA Cloning was used to clone TARP from Chlamydia trachomatis extracted DNA 
into pGEM®-T Easy Vector for later use in the Cloning of p_101AATARP-CRE and p_TARP-CRE. The 
first step is the polyadenilation of the purified PCR fragment generated with Phusion DNA Polymerase in 
the presence of dATP (final concentration of 0.2 mM) and 10X NEB Reaction Buffer. The mixture was 
incubated at 70°C for 15–30 min. Subsequently, TARP was cloned into pGEM®-T Easy Vector (50ng) 
using 2x Rapid Ligation Buffer, pGEM®-T Easy Vector from Promega (50 ng), 16.6 ng (1/3) of the insert 
(adenilated product) and the T4 DNA ligase (3 Weiss unit/µl) from the Promega TA cloning Kit for 1 h 
incubation at room temperature.  
The ligation product was used to transform E. coli TOP10F‘ competent cells like recommended for 
the manufacture using 50 µl of competent cells on a 2 mL tube, incubating it on ice for 30 min. The tubes 
were immersed in a 42°C water bath for 50sec. Immediately after, the cells were returned to ice for 2 min, 
adding later 750 µl of warm SOC medium to each sample. E. coli TOP10F‘ was incubated in a 37°C 
incubator/shaker, allowing the cells to recover and begin expressing penicillin resistance for 1 h (3 cycles 
of E. coli replication). After 1 h, 100 µl of each cells were seeded on IPTG-Xgal-Amp (0.1mM- 40ug/ml-
100µg/ml) blue/white screening and antibiotic selection. 
After an overnight incubation at 37º C, single blue and white colonies were observed and the 
white ones were selected based on the principle of α-complementation of the β-galactosidase gene (cells 
transformed with vectors containing recombinant DNA will produce white colonies and cells transformed 
with non-recombinant plasmids produce blue colonies). To select the right clone the DNA was extracted 
according to the protocol and followed by a restriction test.  
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D. Molecular Cloning - Standard Protocol 
The initial inserts were generated by conventional PCR (Polymerase Chain Reaction) or 
overlapping PCR and then digested, as well as the vector used, with the same couple of restriction 
enzymes (Fast Digest from Thermo Scientific) for 1 h at 37º C. Inactivation of the restriction enzymes 
occurred at 65º C for 20 min. The insert was purified by the QIAquick PCR Purification Kit. After the first 
digestion the linearization of the backbone was checked by gel electrophoresis and later digested with the 
second enzyme in the same conditions. The double digested vector was then dephosphorylated using the 
FASTAP enzyme (Thermo Scientific #EF0654) as recommended by the manufactures. After the 
dephosphorylating the vector was ran in an electrophoresis gel without ethidium bromide (0.7% TAE Gel) 
and stained with methylene blue for further gel extraction of the double digested vector. Both vector and 
insert were quantified by the Nanodrop (peQlab Nanodrop spectrophotometer ND-1000) and by a gel 
electrophoresis using ImageJ for the calculation of the approximate quantity of DNA (pixel densitometry 
analysis), for further ligation. The ligation was performed overnight at 16º C using a 3:1, 1:3 and1:1 ratio of 
vector:insert ratio together with the 10x ligation buffer and 1 µl of T4 DNA Ligase from NEB. For ligation, it 
was always used two controls: (C1) Double-Digested Vector + Ligase and (C2) Double-Digested Vector 
without Ligase. 
The transformation in E. coli TOP10F‘ or JM110 were performed as recommended by the 
manufactures and described above, using SOC medium and growing it overnight at 37º C in LB agar 
plates with the selective antibiotic (Ampicillin). The DNA was extracted, according to the protocol, for 6-12 
selected single colonies and a digestion test was performed to check for presence or absence of the 
desired plasmid. The desired clone was submitted to a DNA extraction according to the protocol and the 
DNA stored at -20º C in TE Buffer. 
 
E. Sequencing 
Both constructed plasmids, p_101AATARP-CRE and p_TARP-CRE, were sequenced by MWG-
eurofins, by the ―SimpleSeq‖ service, using the Sanger sequencing method with a set of primers from 5´to 
3´ spanning 400-500bp. The primers were designed in CloneManager9 and the samples sent according to 
the instructions required by the company. The data, provided by the company, was analyzed using 
CloneManger9. 
 
 
9. Protein detection by Western Blot 
For the sample preparation, 0.3 ml of an E. coli overnight culture with an optical density at 600 nm 
between 1.2 and 2.0; was centrifuge and the pellet resuspended in 60 µl of 2x Sample Buffer (Table II.2) 
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with DTT. The sample was boiled for 10 min at 95º C and vortex. The lysates were frozen at -20º C or 
loaded directly on the gel. 
The SDS-PAGE was carried out using a BioRad (Mini Protean II
TM
) system. A stock solution of 
30% acrylamide plus 0.8% bisacrylamide was used to prepare a 8% polyacrylamide gel (stacking gel at 
4% and resolving gel at 8%). For polymerization of the gel, 0.1% TEMED and 0.5% APS were added. 20μl 
of each sample and 8μl of pre-stained protein ladder (Thermo Scientific #SM1812) were loaded into the 
gel and proteins were separated at 120 V for 2 h. 
Separated proteins by SDS-PAGE were transferred electrophoretically to Immobilon-P 
Polyvinylidene difluoride (PVDF) membranes using the wet blotting method (BioRad Mini Protean II
TM
 
system). PVDF membrane was activated in methanol for 1 min and then rinsed in transfer buffer. 
Transferring protein was carried out for 2 h at 250 mA at 4°C.  
Fot the immunoblotting, the membrane was blocked in solution containing 3% BSA in TBS-T for 
30 min. Further, the membranes were incubated overnight at 4°C in blocking buffer containing primary 
antibody at the appropriate concentration (Table II.3). Membranes were washed with TBS-T twice for 20 
min and incubated with a corresponding secondary antibody in blocking solution for 1 h at RT. After two 
washing steps with TBS-T, for 20 min each, developing reagents (Western Lightning Chemiluminescent 
Reagent Plus (1:1 Western LightningTM PLUS-ECL of Enhanced Luminol Reagent Plus (lot275-13061) 
and Oxidizing Reagent Plus (lot265-13061) – Thermo Scientific)) were applied to detect the specific 
binding of peroxidase. The developing was done in a with Amersha, HyperfilmTM ECL High performance 
chemiluminescence films – GE Healthcare Limited (28906837) with different exposure times. 
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IV. Results  
1. Establishment of the genetic transformation of Chlamydia trachomatis 
serovar D and L2 
To achieve the genetic transformation of Ctr, a set of published papers were studied (Agaisse and 
Derré, 2013; Bauler and Hackstadt, 2014; Wang et al., 2013a, 2013b, 2011) in order to create a functional 
protocol for Ctr L2 and Ctr D transformation. For these transformations, a chlamydial plasmid-based 
shuttle vector described in 2013 was used (Agaisse and Derré, 2013).  
 
A. Chlamydia trachomatis infection 
In order to acquire practice and understand the chlamydial infection cycle, HeLa cells were 
infected with Ctr L2 and Ctr D, in a 12 well plate. A record (Figure IV.1 and Figure IV.2) of their phenotype 
was kept for six days. As shown, Ctr inclusions grew bigger in each observation until occupy the full area 
of the cell. After 4 days for Ctr L2 and 6 for Ctr D, most cells were lysed due to the infection. 
 
Figure IV.1 HeLa cells infected with Ctr L2. A- Non-infected HeLa cells; B- 100% HeLa cells infected with Ctr 
L2 2 d.p.i.; C- HeLa cells lysed by the infection with Ctr L2 4 d.p.i.. The infection medium was change 2 h.p.i. for 
synchronization of the infection. Red arrows show the chlamydial inclusions. 
 
Figure IV.2 HeLa cells infected with Ctr D. A – Non-infected HeLa cells; B- HeLa cells infected with Ctr D 3 
d.p.i.; C- 100% HeLa cells infected with Ctr D 4 d.p.i.. The infection medium was change 2 h.p.i. for synchronization of 
the infection. Red arrows show the chlamydial inclusions. 
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Regarding the lysing time, Ctr L2 lysed all the cells after 4 d.p.i. but in case of Ctr D that only 
happen 6 d.p.i. (data not shown), when the majority of what is visible were cell debris. This highlights that 
both serovars have different time cycles, with different consequences for the infected cells. For Ctr L2, 2 d 
(48 h) are enough to have full grown inclusions and consequently perform re-infection; however for Ctr D, 
3 d (72 h) are necessary.  
Four days post-infection (4 d.p.i.), some infected cells were fixed (Method 5) and stained for the 
presence of chlamydial inclusions (Cy3 – Red), cell actin (Cy2 – Green) and nuclei (Hoechst - DAPI) to 
monitor the infection by confocal microscopy, Figure IV.3. Is possible to see that on the non-Infected HeLa 
cells there were no inclusions, as expected but in the case of cell infected with Ctr L2, these ones have 
great number of inclusions, with a bigger number of inclusions on MOI5 than MOI1, as expected. For the 
cells infected with Ctr D, these have fewer inclusions than Ctr L2, although it is possible to see several 
ones on MOI1 but much more in MOI5 infections. 
 
 
Figure IV.3 Immunofluorescence pictures of HeLa cells infected with Ctr L2 and D, 4 d.p.i.. Pictures 
acquired by confocal microscopy. A-Non-infected HeLa cells; B-Cells infected with Ctr L2 MOI1; C-Cells infected with 
Ctr L2 MOI5; D-Cells infected with Ctr D MOI1; E-Cells infected with Ctr D MOI5. Staining: Hoechst (blue) for DNA 
Cy2 (green) for actin and Cy3 (red) for chlamydial inclusions.  
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B. Plasmid shuttle vector - properties of p2TK2-SW2_IncDProm-
mCherry-IncDTerm 
p2TK2-SW2_IncDProm-mCherry-IncDTerm is a versatile shuttle plasmid (Table III.5 and Figure 
IV.4), generously provided by Agaisse and Derré. This plasmid was used for the transformation of Ctr L2 
and Ctr D, allowing the expression of fluorescent proteins under the control of Chlamydia trachomatis 
IncD promoter and terminator (Agaisse and Derré, 2013). Since this shuttle plasmid will be used for 
transformation of Ctr L2 and Ctr D it was mandatory to demethylated it by amplification on a dam dcm 
negative E. coli strain (E. coli JM110). DpnI that only cleaves dam methylated DNA and EcoRII that does 
not cleave dcm methylated DNA. Thus, as shown in Figure IV.5, the shuttle plasmid, demethylated, was 
not digested by DpnI and it was digested by EcoRII creating 7 fragments, proving the demethylation of the 
plasmid. At the time of the amplification in E. coli TOP10F‘, the colonies and bacterial pellet observed 
were totally red, what drives the conclusion that the mCherry protein is being expressed and therefore 
concluding that IncD promoter works in E. coli as well, what was also described by Agaisse and Derré 
(2013). 
 
 
Figure IV.4 p2TK2-SW2_IncDProm-mCherry-
IncDTerm plasmid (Adapted from Agaisse and 
Derré, 2013). 
 
 
Figure IV.5 p2TK2-SW2_IncDProm-mCherry-
IncDTerm plasmid. Plasmid digested with 
methylation sensitive enzymes, DpnI and EcoRII, for 
dam and dcm methylation sites, respectively, after 
amplification in E. coli JM110. 
 
C. Transformation of Chlamydia trachomatis serovar L2 and D 
The method for the genetic transformation of Ctr L2 and D, described in Methods (6), was applied 
to Ctr L2 and D. The different stages of both transformations, serovars L2 and D, are presented in Figure 
IV.6 and Figure IV.8, respectively, and a description of the observed phenotypes in Table IV.1. 
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Table IV.1 Description of the phenotype during Ctr genetic transformation 
Passage Comments 
P1 Most inclusions were big and vacuolar (Lambden et al., 2006; Skilton et al., 2009). 
P2 A few normal inclusions (non-vacuolar) were observed in this passage. 
P3 Some normal inclusions were routinely recovered in this passage.  
P4 
Some normal inclusions were routinely recovered in this passage. The lysate from the HeLa 
flask was added in the one with McCoy cell monolayer and vice-versa.  
P5 –P7 Normal inclusions were routinely recovered in this passage.  
P8 Only normal inclusions were seen in this passage.  
 
At Passage 0, without the addition of penicillin G, all inclusions presented a wild type phenotype, 
but at Passage 1, 2 days post-re-infection (2 d.p.r.i.), most of the inclusions were large and vacuolar 
demonstrating a persistence phenotype (Figure IV.6-A), as the ones already reported (Lambden et al., 
2006; Skilton et al., 2009). At Passage 2, 3 d.p.r.i., a few normal inclusions were observed as well as 
some with the persistence phenotype (Figure IV.6-B-C). At Passage 4, some normal inclusions were 
observed (Figure IV.6-D)and after Passage 5 the number of these inclusions start to be higher (Figure 
IV.6-E-F), increasing at the same time the penicillin G (Figure IV.6-G-H). Nevertheless, for each 
experiment and passage, regular microscope observations of the infected cells allowed some flexibility in 
deciding precisely when the next passage should be done on the basis of sizes and phenotypes of the 
inclusions. 
 
Figure IV.6 Genetic transformation of Ctr serovar L2 with p2TK2-SW2_IncDProm-mCherry-
IncDTerm plasmid. A - P1 Day2; B - P2 Day2– 0.1 U/ml; C - P3 Day2; D - P4 Day1; E - P6 Day1; F - P6 Day2; G - 
P7 Day1; H - P8 Day2. Blue arrows show the vacuolar inclusions and red arrows the normal inclusions (transformed 
Ctr). From P1 to P5 0.1 U/ml penicillin G was used and after P6 1 U/ml. 
 
Ana da Costa Results 
 
 
Page | 33  
 
To verify the transformation of Ctr L2 with the mCherry expression plasmid, on Passage 9 with 2 
U/ml of penicillin G selection medium, live infected cells were observed under fluorescence microscope to 
visualize the red florescent signal of the transformed Ctr L2 inclusions; all the inclusions exhibited red 
fluorescence representing 100% of transformed Ctr L2 in the infection (Figure IV.7). 
 
Figure IV.7 HeLa229 cells infected with transformed Ctr serovar L2. Acquired in a live cell microscope at 
Passage 9, 2 d.p.r.i., with 2 U/ml penicillin G selection. A-Brightfield; B-Cy3-inclusions; C-Overlay. 
 
For the transformation of Ctr D, which has never been reported, we adopted a similar protocol. 
Normal inclusions were present during all passages under increasing selection of penicillin G selection 
(Figure IV.8).  
 
 
Figure IV.8 Genetic transformation of Ctr serovar D with p2TK2-SW2_IncDProm-mCherry-
IncDTerm plasmid. A- P1 Day2; B- P2 Day2; C- P3 Day2; D- P4 Day1; E- P6 Day2; F-P8 Day2; G- P11 Day3. 
Blue arrows show the vacuolar inclusions and red arrows the normal inclusions (transformed Ctr). P1 to P5 0.1 U/ml 
penicillin G was used; from P6 to P10 1 U/ml and after P11 2 U/ml. 
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In the first passages the cells showed a persistence phenotype that gradually disappeared 
through passages due to the resistance acquired to penicillin G. In Figure IV.8-C and Figure IV.8-E is 
possible to see both phenotypes, persistence and WT for the transformed Ctr. The cells were then 
selected based on their resistance to penicillin G which is visible through a WT (Wild Type) phenotype of 
the inclusions. The tracking of size and phenotype of the inclusions during passaging of the infected cells 
allowed a decision of whether or not to proceed with the next passage.  
Genetic transformation of Ctr D was verified as previously mentioned for Ctr L2 and, as observed 
in Figure IV.9, Ctr D presents red fluorescence for all the inclusions formed at passage 9, 3 d.p.r.i..  
 
 
Figure IV.9 HeLa229 cell line infected with transformed Ctr D. Acquired in a live cell microscope at 
Passage 9, 2 d.p.r.i., with 2 U/ml penicillin G selection. A-Brightfield; B-Cy3-inclusions; C-Overlay.  
 
 
D. Stock preparation 
Subsequently to the transformation of Ctr L2 and Ctr D, both transformed serovars of Chlamydia 
trachomatis with p2TK2-SW2_IncDProm-mCherry-IncDTerm, were used for a stock preparation. After the 
preparation of the Ctr stocks, as described in Method 7, both serovars were used to infect HeLa cells. 
This experiment aimed to determine the titer, as well the ratio of transformed/not transformed Ctr. This 
ratio was not expected to be 100% in P0 (Passage 0) because the same was observed in a stock of 
transformed Ctr L2 with GFP. The infection was performed without penicillin G selection because its use 
in P0, right after the thawing, is stressful for the bacteria and when used in the stock all inclusions 
presented the persistence phenotype (data not shown).  
For Ctr L2, titer of transformed Ctr of 8x10
6
 IFU, approximately 20-30% of the bacteria that are 
infecting HeLa cells were transformed in P0, as shown in Figure IV.10, through analysis by ScanR 
software. Nevertheless, when repassaging the stock with the majority of transformed Ctr L2, the 
population was re-established after only 3 Passages with 1U/mL of penicillin G selection (Figure IV.11). 
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Figure IV.10 HeLa229 cells were infected with Ctr L2 stock. 2 d.p.i. the cells were fixed and labeled for 
Chlamydia inclusion (anti-MOMP) with Cy2 and Hoechst for nuclei using no penicillin G for selection. A- Ctr L2 
mCherry in red dil1:4000; B- Ctr L2 mCherry and Ctr L2 WT in green dil1:4000; C- Ctr L2 mCherry in red dil1:1000; 
D- Ctr L2 mCherry and Ctr L2 WT in green dil1:1000. 
 
 
Figure IV.11 HeLa229 cells infected with Ctr L2 stock. Passage 3 after first infection with mCherry Ctr L2 
stock, using 1U/mL penicillin G selection. A- Brightfield; B- Cy3 filter. 
 
The inclusion size of the transformed Ctr L2 was also analyzed and studied by the ScanR 
software as presented in Figure IV.12. Compared to the WT Ctr L2, the sizes observed for the 20-30% 
transformed Ctr L2 at passage 0 (without penicillin G selection) and the non-transformed ones (70-80%) 
are approximately similar to the 24h.p.i. WT Ctr L2 inclusions. 
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Figure IV.12 Ctr L2 inclusions size 24h.p.i.. CtrL2 WT – Chlamydia trachomatis serovar L2 Wild type 
(Control); CtrL2 mCherry – Chlamydia trachomatis serovar L2 transformed with the p2TK2-SW2_IncDProm-mCherry-
IncDTerm plasmid; NT CtrL2 - Chlamydia trachomatis serovar L2 non-transformed present in the stock. Calculated by 
ScanR and presented using Prism5 software. 
 
In case of the genetically transformed Ctr D stock, with the titer 9,7x10
7
 IFU, approximately 10-
20% of Ctr D was transformed in P0 (without penicillin G selection), as shown in Figure IV.13. Although, 
when proceeding to re-infections with the cell lysates from this stock, most of the Ctr population was 
transformed at passage 3 using 1U/mL of penicillin G selection (Figure IV.14).  
 
Figure IV.13 HeLa229 cell infected with the Ctr D stock. 2d.p.i. the cells were fixed and stained for Chlamydia 
inclusion (anti-MOMP) with Cy2 and Hoechst for the nuclei using no penicillin G for selection. A- Ctr D mCherry in red 
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dil1:4000; B- Ctr D mCherry and Ctr D WT in green dil1:4000; C- Ctr D mCherry in red dil1:1000; D- Ctr D mCherry 
and Ctr D WT in green dil1:1000. 
 
 
Figure IV.14 HeLa229 cell line infected with Ctr D stock. Passage 3 after first infection with Ctr D mCherry 
stock using 1U/mL penicillin G selection. A- Brightfield; B- Cy3 filter. 
 
In relation to the inclusion sizes of the genetically transformed Ctr D, when compared to the WT 
Ctr D, the 10-20% transformed Ctr of the stock has approximately the same size for 24h.p.i. (Figure 
IV.15). However for the 80-90% non-transformed Ctr D presents in the stock, the inclusion size is bigger 
than expected when compared with the WT Ctr D.  
 
 
Figure IV.15 Ctr D inclusions size 24 h.p.i.. Ctr D WT – Chlamydia trachomatis serovar D Wild type (Control); 
Ctr D mCherry – Chlamydia trachomatis serovar D transformed with the p2TK2-SW2_IncDProm-mCherry-IncDTerm 
plasmid; NT Ctr D - Chlamydia trachomatis serovar D non-transformed present in the stock. Calculated by ScanR 
and presented using Prism5 software. 
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2.  Cloning of p_101AATARP-CRE and p_TARP-CRE 
Briefly, the cloning started by the achievement of a plasmid with TARP, fusing it with the CRE 
recombinase in order to construct the p_101AATARP-CRE and p_TARP-CRE, described in Table III.5 
and in Figure III.2. 
 
A. Cloning TARP in pGEM®-T Easy Vector 
As described in the methodology (3), bacterial DNA extraction was performed for both Chlamydia 
trachomatis serovars, D and L2, with a phenol:chloroform based protocol. The concentration achieved, 
given by the NanoDrop, was 12 ng/µl for Ctr D DNA and 20 ng/µl for Ctr L2 DNA.  
The first step for the cloning of p_101AATARP-CRE and p_TARP-CRE was the cloning of Ctr 
TARP gene in pGEM®-T Easy Vector (Table III.5) via TA Cloning (Method (8.C), since it is an easy and 
fast way to clone an insert into a cloning vector in a stable manner. Initially, the TARP gene was amplified 
by PCR, from the previously extracted DNA of Ctr L2 and Ctr D, using primer 1 and primer 2 (Table III.6), 
the products generated (4kb) are shown in Figure IV.16. 
 
Figure IV.16 TARP gene  (approximately 4kb) in pGEM®-T Easy Vector from Ctr L2 and Ctr D. 
Amplified with Primer 1 and Primer 2 (Table III.6). M-1kb Marker (Fermentas); CtrD-TARP gene from Ctr serovar D; 
Ctr2-TARP gene from Ctr serovar L2. 
 
Subsequently, both fragments (TARP from Ctr L2 and Ctr D) were polyadenylated and ligated 
overnight with the pGEM®-T Easy Vector. The Figure IV.17 shows ScaI digestion profile. The expected 
sizes are 2366bp and 4340bp as it is possible to observe for clones D4, D5 and D7 for Ctr D and L1, L3 
and L8 for Ctr L2. The samples selected for the subsequent steps were D4, D7 from Ctr D and L3 and L8 
from Ctr L2. 
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Figure IV.17 TARP in the pGEM®-T Easy Vector digested with ScaI. Digestion made to check the clones 
generated by transformation in E. coli TOP10F‘. M-1kb Marker (Fermentas); C(NC) – control plasmid not digested; C- 
Control plasmid digested with ScaI. 
  
 
B. Backbone plasmid construct (p2TK2-SW2_IncDProm-IncDTerm) 
In order to construct p_101AATARP-CRE and p_TARP-CRE it was necessary to create a 
backbone plasmid that already possesses an antibiotic resistance (ampicillin), an origin of replication in E. 
coli and a Ctr promoter and terminator. The chosen plasmid was the p2TK2-SW2_IncDProm-mCherry-
IncDTerm, used on the genetic transformation of Ctr L2 and D described above (Agaisse and Derré, 
2013).  
In order to use this plasmid it was necessary to remove the mCherry sequence to later substitute 
it with TARP-CRE recombinase fusion protein sequences for the construction of p_101AATARP-CRE and 
p_TARP-CRE. In order to overcome the absence of restriction sites confining the mCherry sequence, 
IncDPromoter and IncDTerminator were amplified with primer 3 and primer 4 (Figure IV.18-A) and primer 
5 and primer 6 (Figure IV.18-B), respectively. After PCR purification of both products, an overlap PCR 
was performed with the products described. Both fragments were complementary to the each other; this 
complementary was given by the IncDPromoter RV primer and IncDTerminator FW primer (Figure IV.18-
D). The product generated by the overlap PCR was 674bp length (Figure IV.18-C) and was then 
extracted by PCR Gel extraction kit from a 0.7% TAE electrophoresis gel stained with methylene blue. 
The overlap PCR product (Figure IV.18-C) was digested with KpnI and EagI as well as the 
p2TK2-SW2_IncDProm-mCherry-IncDTerm plasmid to perform ligation. The ligation product was used to 
transform E. coli TOP10F‘ from which ten clones were analyzed by restriction digestion. Figure IV.19, 
shows the profile of 10 clones double digested with KpnI and EagI. Clones 6, 8 and 10 have created the 
expected fragments (9164bp and 414bp) for the required plasmid (Figure IV.20).  
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As this was the first cloning step the transformation it did have a big efficiency and it was not 
necessary to perform a big screening to find the desirable clone, with plasmid p2TK2-SW2_IncDProm-
IncDTerm.
 
 
Figure IV.18 Overlap PCR of IncDpromoter and IncDTerminator. A- IncDPromoter amplification; B- 
IncDTerminator amplification; C- Product of the overlap PCR; D- Graphic scheme of the overlapping region 
necessary to perform the overlap PCR, generated in Clone Manager 9. 
 
 
 
Figure IV.19 Restriction test for 10 E. coli clones transformed with the Ligation product using KpnI 
and EagI enzymes.  1kbM- 1kb DNA Marker. 
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Figure IV.20 Backbone p2TK2-SW2_IncDProm-IncDTerm plasmid construct. Generated in Clone 
Manager 9. 
 
 
 
C.  p_101AATARP-CRE construction 
To generate p_101AATARP-CRE , 101AA TARP and CRE were amplified with primers 8 and 9 
(336bp product) and primers 10 and 11 (1109bp product), respectively, as shown in Figure IV.21-A and 
Figure IV.21-B. Samples were purified and an overlap PCR was made (Figure IV.21-C) due to the 
complementary given by the primers 9 and 10 in the initial PCRs (Figure IV.21-D). 
The backbone plasmid created before (p2TK2-SW2_IncDProm-mCherry-IncDTerm) was digested 
with NheI restriction ezyme first and after with and ApaI restriction enzyme, as shown in Figure IV.22. The 
insert generated with the overlap PCR was run on a gel and purified. Insert and vector weredigested with 
NheI and ApaI, as it is showed in Figure IV.23. Densitometric analysis (performed with ImageJ) were 
performed to quantify the samples. Insert and vector were ligated overnight. 
The ligation product was transformed in E. coli Top10F´ obtaining numerous colonies. 40 colonies 
were screened by PCR using the Primers 7 and 11 (Table III.6). The results from the PCR were analyzed 
in an electrophoresis gel, and, as shown in Figure IV.24, Clone number 40 is the only one showing the 
correct 1427bp band. 
 
9578bp 
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Figure IV.21 Overlap PCR of 101AA N-Terminal TARP and CRE. A- 101AA N-Terminal TARP 
amplification; B- CRE amplification; C- Product of the overlap PCR; D- graphic scheme of the overlapping region 
necessary to perform the overlap PCR, generated by Clone Manager 9. 
 
 
Figure IV.22 Gel to check linearization of the 
p2TK2-SW2_IncDProm-IncDTerm plasmid 
with NheI (9577bp). 
 
 
Figure IV.23 Gel Quantification of the vector 
(9562bp) and insert (1419bp) used for the 
cloning. 
 
Subsequently, Clone 40 was tested with restriction enzymes KpnI, EagI, ApaI and NheI (Figure 
IV.25) for further confirmation for presence of p_101AATARP-CRE (Figure IV.26). The sequenced of the 
region of the insert in this plasmid (101AATARP-CRE) is available in Supplementary Data 1.A. 
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Figure IV.24 Colony PCR of 18 of the 40 E. coli clones. Analyzed using Primer 3 and 6 from table, creating 
an expected product of 1427bp. NTC- Non-Template Control. 
 
 
 
Figure IV.25 Diagnostic restriction digest of 
Clone 40. Restriction with KpnI and EagI creating 
two bands of 9163bp and 1818bp and ApaI and NheI 
creating two bands of 9562bp and 1419bp, as 
expected. 
 
Figure IV.26 p_101AATARP-CRE construct 
(10981bp). Generated in Clone Manager 9. 
 
 
 
D. p_TARP-CRE construction 
In order to generate p_TARP-CRE, TARP was amplified by PCR from pGEM®-T Easy Vector-
TARP (Table III.5) and digested with SacII and NheI. p_101AATARP-CRE was subsequentially digested 
with the same enzymes, first with SacII (Figure IV.27) and after with NheI (Figure IV.28). This plasmid 
was dephosphorylated and checked on a gel (Figure IV.29).  
10981bp 
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Figure IV.27 Gel to check linearization of the p_101AATARP-CRE plasmid with SacII. 1kb Marker from 
Fermentas was used. ND – Non-digested plasmid; Dig SacII – p_101AATARP-CRE digested with SacII.  
 
 
 
Figure IV.28 Double digested vector by NheI 
and SacII. M1kb – 1kb Marker (Fermentas); NDv- 
Non-digested vector; LinV – Linearized vector; DDV- 
Double-digested Vector dephosphorylated (creating a 
band of 10669bp and 312bp). 
 
 
Figure IV.29 0.7% TAE Gel stained with methylene 
blue. This dephosphorylated vector was used for 
posterior gel extraction. 1kbM – 1kb Marker 
(Fermentas).
 
Samples were quantified with densitometric analysis (Figure IV.30) to calculate the ratios (3:1) for 
the ligation reaction. 
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Figure IV.30 Gel quantification of vector (10669bp) and insert (3024bp) for p_TARP-CRE. Two 
samples of the Double-digested Vector (V1 and V2) and two samples of the Full TARP Insert (Insert1 and Insert2). 
1kbM - 1 kb Marker (Fermentas). 
 
E. coli TOP10F‘ was transformed with the ligation products, from which 14 colonies were 
analyzed with the restriction enzyme PvuI, which should create two bands (8601bp and 5092bp), as 
created by clone 8 in Figure IV.31. 
 
 
Figure IV.31 Restriction test using PvuI enzyme for 14 E. coli clones. The Control is the p_101AATARP-
CRE digested with PvuI creating a fragment of 8601bp and 5092bp- 1kbM – 1kb DNA Marker. 
 
Clone 8 was then tested with restriction enzymes NheI, SacII and AgeI (Figure IV.32) the DNA 
extracted. The cloned insert, resulting in p_TARP-CRE (Figure IV.33), was sequenced, data available in 
Supplementary data 1.B. 
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Figure IV.32 Restriction test to Clone 8. 
Restriction with NheI and SacII creating 10669bp and 
3024bp; and digested with AgeI creating 10324bp and 
3369bp. 1kbM – 1kb DNA Marker 
 
 
 
Figure IV.33 p_TARP-CRE (13693bp). 
Generated in Clone Manager 9. 
 
 
 
 
E. Plasmids demethylation 
A successful transformation of Ctr depends on the methylation status of the inserted DNA (Wagar 
et al., 1992). Therefore p_101AATARP-CRE and p_TARP-CRE, were amplified in E. coli JM110 (dam
-
 
dcm
-
). DNA was extracted and subsequently digested with methylation sensitive restriction enzymes, 
DpnI for dam methylation site (Figure IV.34) and EcoRII for dcm methylation site (Figure IV.35). 
 
 
Figure IV.34 DpnI digestion to prove the 
demethylation of dam site methylation site. 
p_101AATARP-CRE (Plasmid 1) and p_TARP-CRE 
(Plasmid 2). 
 
 
Figure IV.35 EcoRII digestion to prove the 
demethylation of dcm methylation site. 
p_101AATARP-CRE (Plasmid 1) and p_TARP-CRE 
(Plasmid 2).
13693bp 
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F. Expression of CRE recombinase in E. coli 
The correct expression of the recombinant TARP-CRE protein was tested in E. coli TOP10F‘ 
since the driving promoter (IncD) is functional in Ctr and as well in E. coli (Agaisse and Derré, 2013). 
Therefore, p_101AATARP-CRE and p_TARP-CRE were used to transform E. coli Top10F‘ and total 
protein lysates were analyzed by western blot (Figure IV.36). 
The conjugated 101AA TARP-CRE protein ( p_101AATARP-CRE) should has a calculated size 
of 55kDa, while the putative size of full TARP-CRE (p_TARP-CRE) is 150KDa. CRE recombinase was 
detected with a mouse monoclonal antibody (Amersham NA931). 
 
 
Figure IV.36 Western Blot of E. coli TOP10F’ transformed with p_101AATARP-CRE and p_TARP-
CRE using Anti-CRE recombinase Antibody. C-: plasmid without CRE; C+: plasmid with CRE recombinase 
conjugated with Tir protein with an expected size of 45KDa. p_101AATARP-CRE (Plasmid 1) and p_TARP-CRE 
(Plasmid 2). 
 
 
3. Stable labeling of host cells  
A. Transformation of Chlamydia trachomatis L2 with 
p_101AATARP-CRE and p_TARP-CRE 
After the generation of p_101AATARP-CRE and p_TARP-CRE, Ctr L2 was independently 
transformed with both plasmids, using the methodology adopted for the transformation of Ctr L2 with 
p2TK2-SW2_IncDProm-mCherry-IncDTerm plasmid; Figure IV.37 for p_101AATARP-CRE and Figure 
IV.38 for p_TARP-CRE. As observed, at Passage 2 and Passage 3, using 0.1 U/ml of penicillin G 
selection, it is still possible to see both phenotypes: (1) the normal Ctr inclusion phenotype (red arrows) 
and (2) the persistence phenotype (blue arrows) described by Skilton and Lambden (Lambden et al., 
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2006; Skilton et al., 2009) for the non-transformed Ctr L2, due to its non-resistance to penicillin G. 
Nevertheless, on Passage 5 and Passage 6 it is already possible to see almost only normal inclusions 
phenotypes what can lead to the conclusion that the present inclusions are derived from transformed Ctr 
L2 with p_101AATARP-CRE and p_TARP-CRE, respectively.  
 
Figure IV.37 HeLa229 infected with p_101AATARP-CRE . A- P2 Day3 – 0.1 U/ml penicillin G; B- P5 Day 2 - 
0.1 U/ml penicillin G; C- P6 Day3 – 0.1 U/ml penicillin G. Blue arrows show the vacuolar inclusions and the red 
arrows the normal inclusions (transformed Ctr). 
 
 
Figure IV.38 HeLa229 infected with p_TARP-CRE. A- P2 Day3 – 0.1 U/ml penicillin G; B- P5 Day2 – 0.1U/ml 
penicillin G; C- P6 Day2 – 0.1 U/ml penicillin G. Blue arrows show the vacuolar inclusions and the red arrows the 
normal inclusions (transformed Ctr). 
 
B. Labeling of reporter cell line 
The lysates of the transformed Ctr L2 with p_101AATARP-CRE and p_TARP-CRE were used to 
infect HeLa229_mT/mG (reporter cell line) described in the methodology (Method 1). For this step, 
infected cells were regularly monitored at the microscope under fluorescent light as shown in Figure IV.39 
for p_101AATARP-CRE and Figure IV.40 for p_TARP-CRE.  
Both Figure IV.39-B and C show that none of the cells underwent conversion from red to green 
fluorescence after the infection. The arrow in Figure IV.40-A points to transformed inclusions but also this 
cell do not show any red to green in Figure IV.40-B and C (arrow).  
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Figure IV.39 HeLa229_mT/mG infected with p_101AATARP-CRE . P5 Day2 with 0.1 U/mL of penicillin G 
selection. A-Brightfield; B- Cy3 filter; C- GFP filter. Acquired by live cell imaging with different exposure times. 
 
 
Figure IV.40 HeLa229_mT/mG infected with p_TARP-CRE. P5 Day2 with 0.1 U/mL of penicillin G selection. 
A-Brightfield; B- Cy3 filter; C- GFP filter. Acquired by live cell imaging with different exposure times. 
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V. 
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Discussion 
As the aim of this project was to generate a system to label permanently Ctr infected cells, for its 
purpose Ctr was transformed with a shuttle plasmid coding a chlamydial protein (TARP) fused with CRE 
recombinase and a reporter cell line sensitive to CRE recombinase activity was infected. In such a system 
the label of the infected cells will be irreversible and hereditary, becoming the cells detectable during the 
infection process and after the infection is cleared.  
 
1. Fate of Chlamydia trachomatis infected cells 
Intracellular bacteria that reside within a vacuole have the additional challenge of needing to 
traverse two membranes to successfully escape the host cell. For Chlamydia, after infection, the exit can 
occur by two distinct and independent processes, cellular lysis and a packaged release called extrusion 
(Hybiske and Stephens, 2007).  
Chlamydia is also identified as able to establish asymptomatic, persistent infections by several 
mechanisms, including antibiotic resistance, immune evasion, and apoptosis suppression (Mpiga and 
Ravaoarinoro, 2006). In vivo the use of beta lactam antibiotics (as penicillin, for instance) in the 
developmental of the chlamydial cycle retards the transition to EB, resulting in aberrant RB formation 
where the RBs become enlarged and the developmental cycle enters a persistent, non-infectious state by 
blocking peptidoglycan biosynthesis through binding with penicillin binding proteins (Mpiga and 
Ravaoarinoro, 2006; Skilton et al., 2009). 
In the specific case of Ctr, it is reported that it modulates host cell function in ways that convey 
benefits to the pathogen but have severe consequences for the fate of host cells. Ctr induces ROS 
production to support its own growth and, as a result, induces the formation of DSB (Double Strand 
Breaks); Ctr also inhibits subsequent downstream repair and cell-cycle checkpoint activation that typically 
follow DSB induction (Chumduri et al., 2013). This deregulation of host cell signaling and perturbations to 
the host cell chromatin lead to the enforced survival of damaged host cells, which is likely to predispose 
them to transformation and remain so if the pathogen disappears (Lax and Thomas, 2002; O‘Driscoll and 
Jeggo, 2006). Therefore, during chronic infection, the infected cells undergo long term metabolic genomic 
stress and, as hypothesized by Chumduri and colleagues, that epigenetic modifications induced by 
infection are a primary mechanism that could contribute to heritable changes in host cells like the 
accumulation of DNA damage mutations (Chumduri et al., 2013), what needs to be proven in vivo.  
There are increasing evidences that some bacteria can contribute to specific stages in cancer 
development, particularly in chronic infections (Mager, 2006). These pathogens can be involved in the 
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hypothesis that bacterial molecules are necessary for the initiation but not the maintenance of cellular 
transformation (Kuper et al., 2000). The identification of the damaged cells that have been in contact with 
the pathogen could help to determine and describe the link between the pathogen and further 
transformations, like cancer; as the case of Helicobater pylori (Lax and Thomas, 2002). However, the 
mechanisms by which bacteria contribute to cancer formation are complex and not irrefutable proven 
(Vogelmann and Amieva, 2007). In the case of Ctr, recent evidences correlates it with cervical and 
ovarian cancer (Arnheim Dahlström et al., 2011; Koskela et al., 2000; Shanmughapriya et al., 2012). 
Valdivia and colleagues reported that Ctr infections significantly impact the cell cycle of infected cells, with 
evidence for cleavage of the mitotic cyclin and delay in cytokinesis and centrosomes supernumerary. 
These can lead to genomic instability, which in conjunction with the strong anti-apoptotic effect of 
chlamydial infection may explain the epidemiological association between infections and cervical and 
ovarian cancers (Chumduri et al., 2013; Valdivia, 2008). However, the link between Chlamydia and 
cancer and the oncogenic mechanisms are not proved yet.  
Thereby, it is required to develop a tool that can genetically label the cells that were once infected 
with Ctr, in order to study and prove if the mutations that occur while Ctr infection remain and once it is 
cleared; to clarify and link directly the various aspects that were pointed, as: what stress exactly are the 
cells exposed after the infection, is this stress leaving an ―imprint‖ on the cells, is the progeny affected by 
these mutations, is cancer mutations correlated with it or not, between other possible relevant biological 
features. 
 
 
2. A genetic stable cell labeling tool primed by the infection 
In order to construct such a tool for the genetic label of Ctr infected cells, it will imply the use 
different components as a chlamydial secreted protein, as a vector for CRE, and a shuttle vector with a 
chlamydial promoter that will allow the expression of CRE in the infected cells. 
To select the suitable chlamydial secreted protein that delivers the CRE recombinase in the host 
cell, candidates like Inc proteins, CPAF (Chlamydia Protease-like Activity Factor) and TARP were 
considered; the latter was chosen because is extensively described in the literature to be involved in the 
early cycle of Chlamydia during the first hours of infection (Fields et al., 2003; Mehlitz et al., 2010; 
Valdivia, 2008). The advantage of using an early expressed protein for this system is that the fused 
protein TARP-CRE is transcribed contemporary with its chaperon Slc1 (Brinkworth et al., 2011) in the first 
moments of infection to the host cell.  
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The promoter driving the expression of the recombinant TARP-CRE, corresponds to a sequence 
located in the intergenic region upstream (IncD Prom) and downstream (IncD Term) of the incDEFG 
operon (Agaisse and Derré, 2013). The choice of the promoter and terminator regions of the incDEFG 
operon relies on the fact that they are expressed early and throughout the developmental cycle (Agaisse 
and Derré, 2013; Scidmore-carlson et al., 1999). This expression pattern is essential for the purpose of 
the project since if TARP-CRE fusion protein will be expressed early and through all infection cycle, that 
will maximize the chances of efficient induction of the reporter cell line. 
The shuttle plasmid was provided by Agaisse and Derré (Agaisse and Derré, 2013), Figure IV.4. 
The choice of this plasmid relies in the fact that it was already reported a successful genetic 
transformation of Ctr L2 using this vector. This plasmid has a suitable Ctr promoter and terminator (IncD) 
an antibiotic resistance and an origin of replication that works both in E. Coli and in Ctr. 
Two plasmids were constructed, p_101AATARP-CRE with the first 101AA N-terminal of TARP 
and p_TARP-CRE with the full TARP. 101AA TARP was chosen as a secretion signal to fuse with CRE 
recombinase because although normally the Slc1 chaperon binds to the first 200 N-Terminal aminoacids 
of TARP (Brinkworth et al., 2011), Pais and colleagues showed that the 100 N-terminal aminoacids of 
TARP are sufficient for the biding of Slc1 (Pais et al., 2013). As these are the necessary aminoacids to 
bind to the chaperon, it is hypothesized that the fused protein will be trippingly secreted to the host cell. 
The cloning of p_TARP-CRE, with the full sequence of TARP to maximize the chances of secretion if the 
101AA N-terminal TARP are not enough; this cloning step was more complex than p_101AATARP-CRE , 
mainly because of the bigger size of the plasmid, which decreases the E. coli transformation efficiency 
(Chan et al., 2002). 
 
 
3. Functionality of the system 
The described system hypothesizes that transformed Ctr infection can trigger a stable labeling of 
reporter host cells using p_101AATARP-CRE (101AA TARP fused with CRE recombinase) and p_TARP-
CRE (full TARP fused with CRE recombinase), in order to study the fate of these infected cells. To 
achieve this it was necessary to establish a protocol for the genetic transformation of Ctr containing CRE 
to be delivered to the host. As a consequence, as Muzumdar and colleagues described, if a signal, such 
like CRE, is delivered to a reporter cell line sensitive to CRE, as a result the infected cells will be label in a 
ubiquitous and permanently way, enabling their study (Muzumdar et al., 2007). 
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A. Expression of p_101AATarp-CRE and p_TARP-CRE in E. coli 
p2TK2-SW2_IncDProm-IncDTerm plasmid has an E. coli origin of replication (Agaisse and Derré, 
2013), therefore because this plasmid was the backbone used for the generation of p_101AATARP-CRE 
and p_TARP-CRE, the constructed plasmids should be as well. Subsequently to the generation of both 
plasmids, the activity of the promoter was tested in E. coli using an anti-CRE recombinase antibody that 
detects the expression of the recombinant proteins TARP-CRE (Figure IV.36). Both p_101AATARP-CRE 
and p_TARP-CRE, show the expression of the respective encoded recombinant protein of 55 kDa and 
150 kDa, respectively. This experiment proves that p_101AATARP-CRE and p_TARP-CRE are functional 
(in E. coli) and that the construct was correctly generated. 
 
B. Genetic Transformation of Ctr L2 and Ctr D 
In order to track Ctr infected cells, it was necessary to establish a protocol for Ctr L2 and Ctr D 
transformation. The genetic transformation of Ctr was not reported until three years ago, as this pathogen 
is considered a difficult organism to manipulate (Rockey, 2011). The genetic transformation was 
described in some papers since but only for Ctr L2 (Agaisse and Derré, 2013; Bauler and Hackstadt, 
2014; Song et al., 2013; Wang et al., 2011). The attempt to transform Ctr D for the first time is relevant 
because this is one of the genital serovars (D-K) known to be causative agents of the sexually transmitted 
diseases, accounting for up to 60 to 70% of urogenital infections (Kessler et al., 2012; Singh et al.,2003). 
Transforming Ctr with a fluorescent protein allow more detailed studies in vitro and in vivo and using the 
established protocol can also be used for a different via of research, like developmental cycle studies, 
protein-protein interactions, etc., what can be crucial for a better understanding of the chlamydial 
infection.  
As described in the results (1.B), the plasmid used for the genetic transformation of Ctr, as well 
as the backbone for the cloning, was provided by Agaisse and Derré (Agaisse and Derré, 2013), Figure 
IV.4. p2TK2-SW2_IncDProm-mCherry-IncDTerm shuttle plasmid contains the chosen chlamydial 
promoter and terminator (IncD) and the fluorescent protein mCherry. It is important to refer that Ctr is not 
methylated in vivo, its DNA appears to have demethylated dam sites and only low level dcm methylation, 
thus plasmid methylation decreases the transformation efficiency (Wagar et al., 1992). Therefore, use of 
proper demethylated plasmid is crucial for Ctr genetic manipulation. For this reason the shuttle plasmid 
was amplified in a dam dcm deficient E. coli strain (E. coli JM110) and checked using methylation 
sensitive restriction enzymes; DpnI that only cleaves dam methylated DNA and EcoRII that does not 
cleave dcm methylated DNA. Thus, as shown in Figure IV.5, the shuttle plasmid, demethylated, was not 
digested by DpnI and it was digested by EcoRII creating 7 fragments, proving the demethylation of the 
plasmid. 
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To transform Ctr three protocols were chosen as methodological references that reported 
transformation in Ctr L2, the conjunction of details reported on each of them and the practice acquired 
during their performing work to create a new protocol (Method 6) that had a positive outcome 
transformation. Due to the different life cycle of Ctr D, compared to Ctr L2, the days of incubation between 
passages were longer (increasing of 24-36 h). 
p2TK2-SW2_IncDProm-mCherry-IncDTerm is resistant to ampicillin (Agaisse and Derré, 2013), 
which belongs to the penicillin group (Raynor, 1997), allowing the selection of transformed Ctr L2 and D. 
The selection follows the principle that subsequently to the lysis or extrusion of the infected cells, the 
untransformed Chlamydia, present as non-infectious RBs, fail to passage. Thus only transformed EBs 
and a diminishing number of carryover untransformed EBs infect new host cells, which are easily 
detectable by phase contrast microscopy (Skilton et al., 2009; Wang et al., 2011). The phenotype 
between the transformed and non-transformed inclusions is visible because for Ctr sensitive to penicillin 
(non-transformed), the prolonged exposure to penicillin leads to the enlargement of the RBs and 
subsequent expansion of the inclusion (Lambden et al., 2006; Skilton et al., 2009). Therefore, as seen in 
Figure IV.6 and Figure IV.8 for Ctr L2 and Ctr D, respectively, it is possible to recognize the inclusions of 
transformed Ctr because they present the normal phenotype for an inclusion (red arrows) and the non-
transformed ones because they present the persistence phenotype (Lambden et al., 2006; Skilton et al., 
2009). The recovery increases with each passage, until only transformed Ctr remains. 
Concerning the stock preparation, Figure IV.10 and Figure IV.13, the percentage of transformed 
Ctr L2 is 20-30% and for Ctr D is 10-20%. The sizes of inclusions formed when compared with the 
inclusions formed by the WT Ctr L2, 24 h.p.i., are the expected size and similar between them, Figure 
IV.12. However for transformed Ctr D the sizes are the expected as compared with the WT (Figure IV.15) 
but, on the other hand, the inclusions formed by the non-transformed Ctr D (80-90% of the stock) present 
a bigger size. This can be clarified with repetitions of the experiment, but it should be taken in account 
that this was performed in P0 when the ratio transformed:non-transformed is low and the big size of the 
non-transformed Ctr D could be a result of a fusion of non-transformed inclusions because at high 
multiplicities of infection, multiple inclusions fuse into a single inclusion (Richards et al., 2013). However, 
this non-transformed inclusions are not resistant to penicillin G, thus when repassaging it with penicillin G 
selection they will not be part of the infection anymore.  
The established protocol for the transformation of Ctr L2 with p2TK2-SW2_IncDProm-mCherry-
IncDTerm (Method 6), was used to transform Ctr with p_101AATARP-CRE and p_TARP-CRE. LGV 
isolates are a popular choice for laboratory work as they usually grow faster and have less compact 
inclusions (Wang et al., 2013a), thus Ctr L2 was the serovar chosen to start with the stable labeling of 
host cells; in parallel Ctr D was being manipulated to perform further studies. The transformation was 
successful for both plasmids as shown in Figure IV.37 and Figure IV.38 due to the normal inclusions with 
penicillin G selection. Nevertheless, repetition of this experiments for both serovars and as well the 
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performance of a biological assay, as the ability to synthesize and accumulate glycogen within inclusions, 
or by comparing expression of different proteins, etc. (Wang et al., 2011), will bring clearer results on the 
similarities of the transformed Ctr L2 with the WT. 
 
C. Stable labeling of a reporter cell line 
The chosen reporter cell line to use within this study was HeLa229_mT/mG (Toelle et al., 
unpublished), which expresses a membrane-targeted tandem dimer Tomato (mT) prior to CRE-mediated 
excision and membrane-targeted green fluorescent protein (mG) after excision (Livet et al., 2007; 
Muzumdar et al., 2007; Smith, 2011). The double-fluorescent nature of HeLa229_mT/mG provides 
several useful features using CRE recombinase; which must be inserted downstream of a promoter to 
drive its expression, and is the choice of that promoter that primarily defines the specificity of CRE 
expression (Smith, 2011), in this case the chlamydial IncD Promoter.  
The reporter cell line, HeLa229_mT/mG, has the advantage of allowing live visualization and 
ubiquitously labeling of cells that underwent recombination (green) or not (red). This cell line also permits 
lineage tracing because the changes occurring with CRE-mediated are permanent excisions of the 
mTomato sequence and thereby transmitted to their offspring (Muzumdar et al., 2007). There are other 
reporters published in literature like LacZ or Rosa26 LSL GFP. With this reporter the detection of b-
galactosidase activity requires fixation or hypotonic permeabilization of cells, excluding all subsequent 
studies if viable, physically un-manipulated cells are needed. For Rosa26 LSL GFP and its variants, as 
live markers have effectively overcome this disadvantage of LacZ but the brightness of when expressed 
is insufficient to allow a truly complete separation of negative and positive cell populations due to its low 
tissue penetration and high tissue background fluorescence what will make impossible to accurately 
assess their respective developmental potential and to rigorously discriminate between potentially 
alternative fates (Luche et al., 2007).  
After the transformation of Ctr L2 with p_101AATARP-CRE and p_TARP-CRE (Results 2.A), the 
transformed Ctr were used to infected the reporter cell line HeLa229_mT/mG as presented in Results 
2.B. As it is possible to observe in Figure IV.39 and Figure IV.40 for p_101AATARP-CRE and p_TARP-
CRE, respectively, inclusions are present in HeLa229_mT/mG cells in the brightfield, but when observed 
under fluorescence light, it is only possible to see red fluorescence cells and no green fluorescence. The 
lack of shift in the fluorescence could mean one of three things: (1) Ctr L2 is not transformed with 
p_101AATARP-CRE or p_TARP-CRE, (2) Ctr L2 is transformed but the translocation of CRE 
recombinase is not occurring throw the T3SS or (3) the CRE recombinase activity did not occur in host 
cell. Any of these three reasons could be responsible for the presented results and each one should be 
monitor and prove to work or not in future experiments. Thereby, in order to improve this experiment, it 
should be repeated for a longer time frame with increasing penicillin G selection and later performance of 
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a Western blotting against CRE for the lysates of Ctr infected cells, or an immunostaining against CRE or 
by a PCR reaction amplifying CRE to prove more effectively that Ctr is transformed indeed. Also, the 
efficiency of this model is known to be low using the full CRE, from parallel on-going projects with other 
pathogens, suggesting that it can be also a matter of probability that no green cells (expressing mG) were 
observed in the reporter cell line. 
Considering the present results, it is necessary to consider that the bottle-neck of this model is 
the translocation of CRE recombinase to the host cell by T3SS, which is hampered by the unfolding for 
the T3SS secretion and posterior folding of the protein (Cornelis, 2006), protein abundance and proximity 
to the secretion apparatus (Grynberg and Godzik, 2009) between other features that influences T3SS 
activity that might be implicated as well. Lastly, it should also be considered that it is necessary the 
translocation of four CRE recombinases for the recombination activity to occur in the cell, due to its 
function as tetramer (Guo et al., 1997).   
 
 
4. Conclusion and Future perspectives 
In conclusion, being the objective of this project the generation of a tool for lineage tracing of Ctr 
infected cells in order to study its future, the aims proposed were fulfilled. The establishment of the 
genetic transformation protocol for Ctr L2 and Ctr D was successful and generation of two plasmids 
expressing CRE recombinase fused with two different secretions signals of Ctr (101AA TARP and the full 
TARP), that express CRE correctly were also accomplished. Finally, this system was tested for the first 
time in a reporter cell line (HeLa229_mT/mG) but without irrefutable postivite results. In the future, it is 
important to perform and repeat some experiments that will check the successful transformation of Ctr L2 
with p_101AATARP-CRE and p_TARP-CRE and translocation of CRE, for a better understanding of the 
lack of red fluorescent HeLa229_mT/mG cells in the observations. An improvement in the results could 
also be achieved by developing the use of different methodologies for the stable labeling of host cells, 
such as the use of Split-CRE recombinase instead of the full CRE recombinase or the use of a TEV 
protease combined with CRE recombinase (TEV-CRE System), linked to the inner cell membrane of the 
host. These two alternatives could help the improvement the system because for Split-CRE recombinase 
the length of the fused protein will be smaller when folded what will improve the secretion through T3SS. 
TEV-CRE system, can also benefit the labeling model, because the system is not dependent on the 
translocation or not of CRE recombinase through the T3SS, from the pathogen to the host; it´s only 
necessary the trigger signal that can be a common chlamydial effector. 
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This project, still ongoing, has set the basis for further developments of the primed genetic 
labelling of infected cells using Ctr. However, this new system is under improvement and it will be used as 
a part of a future PhD project that will develop and improve the presented results and as well trying 
possible alternatives, in order to perform the stable labeling of Ctr infected cells allowing its tracing and 
study. 
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VII. Supplementary data 
1. Sequencing Data 
A. p_101AATARP-CRE 
Backbone is p2TK2-SW2 described in Agaisse and Derré (Agaisse and Derré, 2013) 
Insert (101AATARP-CRE) 
GCTAGCATGACGAATTCTATATCAGGTGATCAACCTACTGTTACAACTTTTACATCATCAACCACTTCGGCATCAGGTGCTTCCGGATCTCTGGGAGCTTCTTCTGTATCTACT
ACCGCAAACGCTACAGTTACACAAACAGCAAACGCAACAAATTCAGCGGCTACATCTTCTATCCAAACGACTGGAGAGACTGTAGTAAACTATACGAATTCAGCCTCCGCCC
CCACTGTAACTGTATCGACCTCCTCTTCTTCCACACAAGCCACAGCCACTTCGAATAAAACTTCCCAAGCCGTTGCTGGAAAACCGCGGGCCAGCCCTAGCAACCCTGGCG
CCAGCAACGGCAGCGCCGGCATGCCCAAGAAGAAGAGGAAGGTGTCCAATTTACTGACCGTACACCAAAATTTGCCTGCATTACCGGTCGATGCAACGAGTGATGAGGTTC
GCAAGAACCTGATGGACATGTTCAGGGATCGCCAGGCGTTTTCTGAGCATACCTGGAAAATGCTTCTGTCCGTTTGCCGGTCGTGGGCGGCATGGTGCAAGTTGAATAACC
GGAAATGGTTTCCCGCAGAACCTGAAGATGTTCGCGATTATCTTCTATATCTTCAGGCGCGCGGTCTGGCAGTAAAAACTATCCAGCAACATTTGGGCCAGCTAAACATGCT
TCATCGTCGGTCCGGGCTGCCACGACCAAGTGACAGCAATGCTGTTTCACTGGTTATGCGGCGGATCCGAAAAGAAAACGTTGATGCCGGTGAACGTGCAAAACAGGCT 
CTAGCGTTCGAACGCACTGATTTCGACCAGGTTCGTTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTTCTGGGGATTGCTTATAACACCCTGTT
ACGTATAGCCGAAATTGCCAGGATCAGGGTTAAAGATATCTCACGTACTGACGGTGGGAGAATGTTAATCCATATTGGCAGAACGAAAACGCTGGTTAGCACCGCAGGTGTA
GAGAAGGCACTTAGCCTGGGGGTAACTAAACTGGTCGAGCGATGGATTTCCGTCTCTGGTGTAGCTGATGATCCGAATAACTACCTGTTTTGCCGGGTCAGAAAAAATGGT
GTTGCCGCGCCATCTGCCACCAGCCAGCTATCAACTCGCGCCCTGGAAGGGATTTTTGAAGCAACTCATCGATTGATTTACGGCGCTAAGGATGACTCTGGTCAGAGATAC
CTGGCCTGGTCTGGACACAGTGCCCGTGTCGGAGCCGCGCGAGATATGGCCCGCGCTGGAGTTTCAATACCGGAGATCATGCAAGCTGGTGGCTGGACCAATGTAAATAT
TGTCATGAACTATATCCGTAACCTGGATAGTGAAACAGGGGCAATGGTGCGCCTGCTGGAAGATGGCGATTAGGTCGAGGGCCCGG 
 
 
 
B. p_TARP-CRE  
Backbone is p2TK2-SW2 described in Agaisse and Derré (Agaisse and Derré, 2013) 
Insert (TARP-CRE) 
CTAGCATGACGAATTCTATATCAGGTGATCAACCTACTGTTACAACTTTTACATCATCAACCACTTCGGCATCAGGTGCTTCCGGATCTCTGGGAGCTTCTTCTGTATCTACTA
CCGCAAACGCTACAGTTACACAAACAGCAAACGCAACAAATTCAGCGGCTACATCTTCTATCCAAACGACTGGAGAGACTGTAGTAAACTATACGAATTCAGCCTCCGCCCC
CACTGTAACTGTATCGACCTCCTCTTCTTCCACACAAGCCACAGCCACTTCGAATAAAACTTCCCAAGCCGTTGCTGGAAAAATCACTTCTCCAGATACTTCAGAAAGCTCAG
AAACTAGCTCTACCTCATCAAGCGATCATATCCCTAGCGATTACGAGCCGATAAGCACTACTGAAAATATTTATGAGAATATTTATGAGAGTATTGATGACTCTAGCACAAGTG
GCCCAGAAAATACGAGTGGTGGTGCAGCAGCACTCAATTCTCTAAGAGGCTCCTCCTACAGCAATTATGACGATGCTGCTGCTGATTACGAGCCGATAAGCACTACTGAAAA
TATTTATGAGAGTATTGATGACTCTAGCACAAGTGACCCAGAAAATACGAGTGGTGGTGCAGCAGCACTCAATTCTCTAAGAGGCTCCTCCTACAGCAATTATGACGATGCTG
CTGCTGATTACGAGCCGATAAGCACTACTGAAAATATTTATGAGAATATTTATGAGAGTATTGATGACTCTAGCACAAGTGGCCCAGAAAATACGAGTGGTGGTGCAGCAGCA
CTCAATTCTCTAAGAGGCTCCTCCTACAGCAATTATGACGATGCTGCTGCTGATTACGAGCCGATAAGCACTACTGAAAATATTTATGAGAGTATTGATGACTCTAGCACAAG
TGACCCAGAAAATACGAGTGGTGGTGCAGCAGCAGCACTCAATTCTCTAAGAGGCTCCTCCTACAGCAATTATGACGATGCTGCTGCTGATTACGAGCCGATAAGCACTACT
GAAAATATTTATGAGAGTATTGATGACTCTAGCACAAGTGACCCAGAAAATACGAGTGGTGGTGCAGCAGCACTCAATTCTCTAAGAGGCTCCTCCTACAGCAATTATGACGA
TGCTGCTGCTGATTACGAGCCGATAAGCACTACTGAAAATATTTATGAGAATATTTATGAGAGTATTGATGGCTCTAGCACAAGTGACCCAGAAAATACGAGTGGTGGTGCAG
CAGCAGCACTCAATTCTCTAAGAGGCTCCTCCTACACAACAGGGCCTCGTAACGAGGGTGTATTCGGCCCTGGACCGGAAGGACTACCAGACATGTCTCTTCCTTCATACG
ATCCTACAAATAAAACCTCGTTATTGACTTTCCTCTCCAACCCTCATGTAAAGTCGAAAATGCTTGAAAACTCGGGGCATTTCGTCTTCATTGATACAGATAGAAGTAGTTTCA
TTCTTGTTCCTAACGGAAATTGGGACCAAGTCTGTTCAATTAAAGTTCAAAATGGAAAGACCAAAGAAGATCTCGACATCAAAGACTTGGAAAACATGTGTGCAAAATTCTGTA
CAGGGTTTAACAAATTCTCTGGTGACTGGGACAGTCGTGTAGAACCTATGATGTCAGCCAAAGCTGGAGTGGCCAGCGGAGGCAATCTTCCCAATACAGTGATTATCAATAA
TAAATTCAAAACTTGCGTTGCTTATGGTCCTTGGAATAGCCGGGAAGCAAGTTCTGGTTATACACCTTCTGCTTGGAGACGTGGTCATCAAGTAAATTTTGGAGAAATTTTTGA
GAAAGCCAACGACTTTAATAAAATCAACTGGGGAACTCAAGCCGGGCCTAGTAGCGAAGACGATGGCATTTCCTTCTCCAATGAAACTCCTGGAGCTGGTCCTGCAGCTGCT
CCATCACCAACGCCATCCTCTATTCCTGTCATCAATGTCAATGTCAACGTTGGCGGAACTAATGTGAATATTAGAGATACGAATGTCAACACGACTAACACCACACCAACAAC
TCAATCTACAGACGCCTCTACAGATACAAGCGATATCGATAACATAAATACCAACAACCAAACTGATGATATCAATACGACAGACAAAGACTCTGACGGAGCTGGTGGAGTCA
ATGGCGATATATCCGAAACAGAATCCTCTTCTGGAGATGATTCAGGAAGTGTCTCTTCCTCAGAATCAGACAAGAATGCCTCTGTCGGAAATGACGGACCTGCTATGAAAGA
TATCCTTTCTGCCGTGCGTAAACACCTAGACGTCGTTTACCCTGGCGACAATGGTGGTTCTACAGAAGGACCTCTCCAAGCTAACCAAACTCTTGGAGATATCGTCCAGGAT
ATGGAAACAACAGGGACATCCCAAGAAACCGTTGTATCCCCATGGAAAGGAAGCACTTCTTCAACGGGATCAGCAGGAGGAAGTGGTAGCGTACAAACACTACTGCCTTCA
CCACCTCCAACCCCATCAACTACAACATTAAGAACGGGCACAGGAGCTACCACCACATCCTTGATGATGGGAGGACCAATCAAAGCTGACATAATAACAACTGGTGGCGGA
GGACGAATTCCTGGAGGAGGAACGTTAGAAAAGCTGCTCCCTCGTATACGTGCGCACTTAGACATATCCTTTGATGGGCAAGGCGATCTCGTAAGTACTGAAGAGCCTCAG
CTTGGCTCGATTGTAAACAAATTCCGCAAAGAAACTGGTTCAGGAGGAATCGTAGCTTCCGTTGAGAGTGCTCCAGGCAAGCCGGGATCTGCACAGGTCTTAACAGGTACA
GGGGGAGATAAAGGCAACCTATTCCAAGCAGCTGCCGCAGTCACCCAAGCCTTAGGAAATGTTGCAGGGAAAGTCAACCTTGCGATACAAGGCCAAAAACTATCATCCCTA
GTCAATGACGACGGGAAGGGGTCTGTTGGAAGAGATTTATTCCAAGCAGCAACCCAAACAACTCAAGCGCTAAGCTCACTGATTGATACCGTAGGACCGCGGGCCAGCCCT
AGCAACCCTGGCGCCAGCAACGGCAGCGCCGGCATGCCCAAGAAGAAGAGGAAGGTGTCCAATTTACTGACCGTACACCAAAATTTGCCTGCATTACCGGTCGATGCAAC
GAGTGATGAGGTTCGCAAGAACCTGATGGACATGTTCAGGGATCGCCAGGCGTTTTCTGAGCATACCTGGAAAATGCTTCTGTCCGTTTGCCGGTCGTGGGCGGCATGGTG
CAAGTTGAATAACCGGAAATGGTTTCCCGCAGAACCTGAAGATGTTCGCGATTATCTTCTATATCTTCAGGCGCGCGGTCTGGCAGTAAAAACTATCCAGCAACATTTGGGC
CAGCTAAACATGCTTCATCGTCGGTCCGGGCTGCCACGACCAAGTGACAGCAATGCTGTTTCACTGGTTATGCGGCGGATCCGAAAAGAAAACGTTGATGCCGGTGAACGT
GCAAAACAGGCTCTAGCGTTCGAACGCACTGATTTCGACCAGGTTCGTTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTTCTGGGGATTGCTT
ATAACACCCTGTTACGTATAGCCGAAATTGCCAGGATCAGGGTTAAAGATATCTCACGTACTGACGGTGGGAGAATGTTAATCCATATTGGCAGAACGAAAACGCTGGTTAG
CACCGCAGGTGTAGAGAAGGCACTTAGCCTGGGGGTAACTAAACTGGTCGAGCGATGGATTTCCGTCTCTGGTGTAGCTGATGATCCGAATAACTACCTGTTTTGCCGGGT
CAGAAAAAATGGTGTTGCCGCGCCATCTGCCACCAGCCAGCTATCAACTCGCGCCCTGGAAGGGATTTTTGAAGCAACTCATCGATTGATTTACGGCGCTAAGGATGACTCT
GGTCAGAGATACCTGGCCTGGTCTGGACACAGTGCCCGTGTCGGAGCCGCGCGAGATATGGCCCGCGCTGGAGTTTCAATACCGGAGATCATGCAAGCTGGTGGCTGGA
CCAATGTAAATATTGTCATGAACTATATCCGTAACCTGGATAGTGAAACAGGGGCAATGGTGCGCCTGCTGGAAGATGGCGATTAGGTC 
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Title of the thesis: Fate of Chlamydia trachomatis infected cells 
University: Universidade Nova de Lisboa (UNL) 
Faculty: Faculdade de Ciencias e Tecnologia (FCT) 
Faculty supervisor: Dr. Pedro Viana Baptista 
 
 
Projects 
Project No. Title/short description Status 
MB079 
Fate of Chlamydia trachomatis infected cells (Cells that were previously in 
contact with Chlamydia trachomatis can be labelled using the double-
fluorescent CRE system. Goal: Label Chlamydia trachomatis (serovar L2 
and D) previously infected cells. 
Active 
 
 
 
Seminar and course participation  
Date Type/subject Remarks  
10/10/2013 
BLSC Seminar - Jacques Neefjes (The 
Netherlands cancer Institute) 
"How Salmonella causes cancer" 
16/01/2014 
BLSC Seminar - Maria Manuel Mota 
(Universidade de Lisboa, Portugal) 
"Host-Plasmodium interactions: 
Understanding to intervene" 
13/03/2014 
Karina Xavier (Instituto Gulbenkian de 
Ciência, Oeiras, Portugal) 
"Manipulating interspecies quorum sensing 
in bacterial consortia" 
 
 
 
Ana da Costa Supplementary data 
 
 
Page | 67  
 
 
Internal presentations  
Date Type/subject Remarks 
24/10/2013 Project presentation and discussion Within the Genetic System Club 
10/12/2013 Project updates and Review of Literature Within the Chlamydia Club 
23/01/2014 Project updates presentation  Within the Departmental Retreat  
24/01/2014 Review of Chlamydia T3SS Within the Departmental Retreat 
27/02/2014 Crispr-Cas System Review Within the Genetic System Club 
31/03/2014 Tips and Tricks (―i-lab Apps‖) Within the Departmental Seminar 
2/06/2014 Project Final Presentation Within the Departmental Seminar 
 
 
 
 
Regular/occasional participation in departmental seminars, discussion clubs etc. 
Period (from-to) Type/subject Remarks (frequency: occ./reg./etc.) 
September – Present Chlamydia Club Bi-weekly 
September – Present Genetic System Club Bi-weekly 
September – Present Cells and Cancer Club Bi-weekly 
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General methods deposited 
No. Title Date 
ARC003.A Infection of cells with Chlamydia trachomatis (serovar L2 and D) 04.09.2013 
ARC003.E Immunofluorescence Staining (General method) 17.09.2013 
ARC003.D Transformation of Chlamydia trachomatis 11.10.2013 
ARC003.H TA Cloning 11.11.2013 
ARC003.N Molecular Cloning (General method) 11.02.2014 
 
